# ent

id: cord-254580-nhpjvgt4
type: ORG
entity:
  the International Psoriasis Council Systemic Treatment of Adult Atopic Dermatitis A Review Systematic Review


id: cord-264264-7j3xirfg
type: WORK_OF_ART
entity:
  The First Endogenous Herpesvirus Identified in the Tarsier Genome and Novel Sequences from Primate Rhadinoviruses and Lymphocryptoviruses Genomewide Function Conservation and Phylogeny in the Herpesviridae IL 12 family of


id: cord-296128-kjoi54ea
type: WORK_OF_ART
entity:
  A Clinical Histopathological and Laboratory Study of 19 Consecutive Italian Paediatric Patients With Chilblain Like Lesions Lights and Shadows on the Relationship With COVID 19 Infection Online


id: cord-296128-kjoi54ea
type: LAW
entity:
  the COVID 19 Pandemic A Consequence of Lifestyle Changes Due to Lockdown Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents


id: cord-309813-qojacnli
type: ORG
entity:
  the United States Food and Drug Administration Laboratory Monitoring During Systemic Terbinafine Therapy for Pediatric Onychomycosis Retrospective


id: cord-309813-qojacnli
type: ORG
entity:
  the United States Food and Drug Administration Retrospective Analysis of Laboratory Abnormalities in Patients Prescribed Terbinafine


id: cord-290137-3jyhc63d
type: DISEASE
entity:
  Rymaszewska Joanna Matusiak Łukasz title Mental health status of health care workers during the COVID


id: cord-317323-wp3vh4c1
type: ORG
entity:
  Specialised Ventilation for Healthcare Premises Part A Design and Installation Estates and Facilities Division London


id: cord-336384-sollv92j
type: CHEMICAL
entity:
  acetate flutamide bicalutamide nilutamide topilutamide enzalutamide apalutamide dienogest drospirenone medrogestone nomegestrol acetate promegestone


id: cord-335104-8b2tpbsh
type: PROTEIN
entity:
  Interleukin 17 date 2020 07 27 journal Dermatol Ther DOI 10 1111 dth 14011 sha 375c60f998d00d12bf2e260d905c209603a7d913 doc_id 335104 cord_uid 8b2tpbsh


id: cord-335104-8b2tpbsh
type: GGP
entity:
  Interleukin 17 date 2020 07 27 journal Dermatol Ther DOI 10 1111 dth 14011 sha 375c60f998d00d12bf2e260d905c209603a7d913


id: cord-323965-6mzzibj8
type: CELL_LINE
entity:
  India United Kingdom Philippines Australia Sweden Norway Switzerland and South Africa An online meeting of the consensus group members


id: cord-323965-6mzzibj8
type: WORK_OF_ART
entity:
  Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID 19 Infection A Systematic Literature Review Way ahead Post Covid 19 Lockdown in India Preparing


id: cord-323965-6mzzibj8
type: ORG
entity:
  N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel A Randomized Clinical Trial Transmission


id: cord-323965-6mzzibj8
type: ORG
entity:
  Spread Environmental Cleaning Guidelines for Healthcare Settings Summary Document Summary of Recommendations Human


# bib

id: cord-254580-nhpjvgt4
author: Ricardo, Jose W.
date: 2020-05-27
url: https://www.ncbi.nlm.nih.gov/pubmed/32458536/
doi: 10.1111/dth.13687
title:
  Considerations for Safety in the Use of Systemic Medications for Psoriasis and Atopic Dermatitis during the COVID‐19 pandemic

abstract:
  Coronavirus disease 2019 (COVID‐19), is responsible for at least 2,546,527 cases and 175,812 deaths as of April 21, 2020. Psoriasis and atopic dermatitis are common, chronic, inflammatory skin conditions, with immune dysregulation as a shared mechanism; therefore, mainstays of treatment include systemic immunomodulating therapies. It is unknown whether these therapies are associated with increased to COVID‐19 susceptibility or worse outcomes in infected patients. In this review, we discuss overall infection risks of non‐biologic and biologic systemic medications for psoriasis and atopic dermatitis, and provide therapeutic recommendations. In summary, in patients with active infection, systemic conventional medications, the JAK inhibitor tofacitinib, and biologics for psoriasis should be temporarily held until there is more data; in uninfected patients switching to safer alternatives should be considered. Interleukin (IL)‐17, IL‐12/23 and IL‐23 inhibitors are associated with low infection risk, with IL‐17 and IL‐23 favored over IL‐12/23 inhibitors. Pivotal trials and postmarketing data also suggest that IL‐17 and IL‐23 blockers are safer than TNF‐blockers. Apremilast, acitretin and dupilumab, have favorable safety data, and may be safely initiated and continued in uninfected patients. Without definitive COVID‐19 data, these recommendations may be useful in guiding treatment of psoriasis and atopic dermatitis patients during the COVID‐19 pandemic. This article is protected by copyright. All rights reserved.


id: cord-254628-706vpjsv
author: Stewart, Claire R.
date: 2020-06-03
txt: ./txt/cord-254628-706vpjsv.txt
cache: ./cache/cord-254628-706vpjsv.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32495403/
doi: 10.1111/dth.13749
abstract: nan
summary:
  1 Despite appropriate precautions to reduce transmission risk, many dermatology faculty, residents, staff, and their families are at increased risk for COVID-19 infection while caring for patients. As stay at home orders expire, delayed surgeries and in-person semi-urgent appointments will be scheduled, with increased patient volume and heightened COVID-19 infection risk. 2 Those with comorbidities, including hypertension, diabetes, and obesity, are at even higher risk for hospitalization substantiated by a case series of 5700 individuals hospitalized with confirmed COVID-19 infection. 5 While limited data is available on pregnant women with COVID-19, early reports and lessons from other severe respiratory infections, including Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome, suggest that pregnant women may be at increased risk for complications. To reduce risk of COVID-19 infection acquired in the workplace, we must maintain an adequate supply of personal protective equipment (PPE) and enforce social distancing.

title:
  Safeguarding Dermatologist Attendings and Residents Amid the COVID‐19 Pandemic: Focus on Special Populations


id: cord-255583-kgph7lr8
author: Kutlu, Ömer
date: 2020-04-24
url: https://doi.org/10.1111/dth.13383
doi: 10.1111/dth.13383
abstract: nan
title:
  A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID‐19: Will cases of psoriasis increase after COVID‐19 pandemic?


id: cord-258039-046s47v6
title: Dermatological procedures amidst Covid‐19: when and how to resume
author: Jindal, Anuradha
date: 2020-05-12
url: https://doi.org/10.1111/dth.13561
doi: 10.1111/dth.13561
abstract:
  The pandemic of covid‐19 has captivated more than 3 Million people across the globe affecting the dermatology practice as well. Due to the novel nature of the virus and concomitant lack of research, standard guidelines have not been set in place regarding the procedures. Currently, due to fear and spread of coronavirus aesthetic practice has taken a seat back. Dermatologic surgeon/aesthetician have to be prepared for the forthcoming alterations in the practice and adjust to the necessary precautionary methods. This articles aims to prepare dermatologist for the upcoming difficulties and precautions to be taken for conducting procedures in amidst of coronavirus. This article is protected by copyright. All rights reserved.


id: cord-263882-s5oxr6es
author: Najar Nobar, Niloufar
date: 2020-06-18
url: https://www.ncbi.nlm.nih.gov/pubmed/32558193/
doi: 10.1111/dth.13867
title:
  Patients with specific skin disorders who are affected by COVID‐19: what do experiences say about management strategies? : A systematic review

abstract:
  BACKGROUND AND AIM: In patients with dermatologic disorders who are affected by new corona virus, we know little about course (underlying disease and new onset‐infection) and the most proper management strategies include both issues that are what this systematic review targets. METHOD: Databases of PubMed, Scopus, Google Scholar, Medscape and CEBD coronavirus dermatology resource of Nottingham University searched completely and initial 237 articles selected to further review and finally nine articles (including 12 patients) entered to this study. RESULT: from 12 patients with chronic underlying dermatologic disease treated with systemic therapies, only one patient required ICU admission, the others have been treated for mild‐ moderate symptoms with conventional therapies. The biologic or immunosuppressive/ Immunomodulator agents has been ceased during the course of disease. The course of COVID‐19 its management was as similar as normal populations. Their underlying dermatologic disease was exacerbating from mild to moderate. Their treatment has been continued as before, after the symptoms improved. CONCLUSION: Exacerbation of patients underlying dermatologic disease is mild‐ moderate. Discontinuing the treatment in the acute period of COVID and the restart after recovery may prevent severe recurrence in these patients. This article is protected by copyright. All rights reserved.


id: cord-264264-7j3xirfg
title: CORONAVIRUS‐DAYS IN DERMATOLOGY
author: TüRsen, Ümit
date: 2020-04-15
url: https://doi.org/10.1111/dth.13421
doi: 10.1111/dth.13421
abstract:
  Severe acute respiratory syndrome‐corona virus‐2 (SARS‐CoV‐2), which causes coronavirus disease 2019 (COVID‐19), is highly contagious and a particularly popular problem in all around the World and also in all departments of every hospital. In order to protect the well‐being of healthcare providers while providing a sufficient workforce to respond to the coronavirus disease (COVID‐19) are vital for pandemic planning. In this article, we will discuss this problem from a dermatological aspect. This article is protected by copyright. All rights reserved.


id: cord-265052-hfuvm1oh
author: Turan, Çağrı
date: 2020-06-12
url: https://doi.org/10.1111/dth.13804
doi: 10.1111/dth.13804
title:
  Change of the diagnostic distribution in applicants to dermatology after COVID ‐19 pandemic: What it whispers to us?

abstract:
  We aim to evaluate the change in the diagnostic spectrum in dermatology outpatient applications compared to before COVID‐19. All patients were enrolled from the Department of Dermatology between February 12 and May 8, 2020, the duration of 4 weeks before COVID‐19 and eight weeks after were analyzed in 3 parts consisting of 4 weeks. Data obtained from the database such as age, gender, diagnoses were anonymized. Repeated applications with the same diagnosis in ten days after the first presentation were ignored. Compared to the pre‐outbreak, there was a 3.5‐fold decrease in dermatology applications in the first month after COVID‐19 and an 8.8‐fold in the second month. We found a significant increase in the frequency of diagnoses such as generalized pruritus, pityriasis rosea, alopecia areata, bacterial skin/mucosa diseases, and zona zoster after COVID‐19. The frequency declined in diseases such as verruca vulgaris, hyperpigmentation, skin tag, melanocytic nevus, seborrheic keratosis/solar lentigo. It has been found that the frequencies of most diseases, including acne (⁓25% of patients), did not change. We think that many factors, such as affecting the quality of life, risk perception, increased stress burden may cause a change in the diagnostic distribution of the dermatology applications. This article is protected by copyright. All rights reserved.


id: cord-265921-0sb59rmm
author: Do, Mytrang H.
date: 2020-05-15
txt: ./txt/cord-265921-0sb59rmm.txt
cache: ./cache/cord-265921-0sb59rmm.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13592
doi: 10.1111/dth.13592
abstract: nan
summary:
  title: Recommendations for personal protective equipment and smoke evacuation for dermatologic surgeries amid the COVID‐19 crisis Currently, elective dermatologic procedures (ablative laser procedure, laser hair removal) are deferred, with only emergency dermatological surgeries being performed to lessen viral spread and preserve personal protective equipment (PPE). Since SARS-CoV-2 may be transmitted through aerosols 2 , it is critical to reexamine recommended protective measures for dermatologic surgery. The use of fitted respirator or surgical masks and smoke evacuators was recommended to minimize the infectious, inhalation, chemical and mutagenic risks of surgical smoke prior to COVID-19 1 . The Centers for Disease Control and Prevention (CDC) recommends N95 respirator use for healthcare workers participating in aerosol-generating procedures (AGP) 3 . In an intubation simulation 5 , secretions were recovered from exposed skin (i.e. neck and ears) and hair of healthcare providers following two coughing episodes despite use of N95 respirators, eye protection, gowns, and gloves, suggesting that use of standard PPE is likely insufficient.

title:
  Recommendations for personal protective equipment and smoke evacuation for dermatologic surgeries amid the COVID‐19 crisis


id: cord-270140-omr30shm
title: Clinical and histopathological findings of cutaneous manifestations of COVID19 patients
author: Albuquerque Brandão, Maria Girlane Sousa
date: 2020-07-07
txt: ./txt/cord-270140-omr30shm.txt
cache: ./cache/cord-270140-omr30shm.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13926
doi: 10.1111/dth.13926
summary:
  title: Clinical and histopathological findings of cutaneous manifestations of COVID19 patients The evidence was analyzed in PubMed, CINAHL, Cochrane, Web of Science and Scopus, with the search strategy (covid 19 OR covid‐19 OR corona OR coronavirus OR sars‐cov‐2) AND (cutaneous or cutaneous manifestations OR), and 17 studies were included, involving 351 cases with COVID19 and skin manifestations. To comprehend how COVID19 causes dermatological alterations, affected areas, types of cutaneous manifestations, the period of appearance, cure and histological findings can provide subsidies for the disease''s early recognition, to support a more effective clinical management of cutaneous lesions and give assistance in the screening and risk stratification 5 . The study''s object is to identify clinical and histopathological findings of cutaneous manifestations of COVID19 patients. The study''s object is to identify clinical and histopathological findings of cutaneous manifestations of COVID19 patients. Histopathological findings suggest spongiosis, thrombogenic vasculopathy and perivascular infiltration of lymphocytes.

abstract:
  COVID19 became pandemic since this is a disease with a high infection rate. The study's object is to identify clinical and histopathological findings of cutaneous manifestations of COVID19 patients. The evidence was analyzed in PubMed, CINAHL, Cochrane, Web of Science and Scopus, with the search strategy (covid 19 OR covid‐19 OR corona OR coronavirus OR sars‐cov‐2) AND (cutaneous or cutaneous manifestations OR), and 17 studies were included, involving 351 cases with COVID19 and skin manifestations. The lesions were classified mainly as maculopapular, erythematous, vesicular and urticarial. Histopathological analyzes suggest a predominance of spongiosis, perivascular infiltrate of lymphocytes and thrombogenic vasculopathy. This article is protected by copyright. All rights reserved.


id: cord-270951-6nq3jwgr
title: COVID‐19 and psoriasis: Should we fear for patients treated with biologics?
author: Amerio, Paolo
date: 2020-05-05
url: https://www.ncbi.nlm.nih.gov/pubmed/32314483/
doi: 10.1111/dth.13434
abstract:
  The new coronavirus pandemic poses question and challenges for dermatologists. One of question is if psoriasis patients treated with immunomodulating and immunosuppressive drugs have to discontinue their treatment in the midst of fears for the infection and its consequences. One of the challenges is how can we support our patients in this critical time. Previous coronaviruses outbreaks reports, current published evidences on pathogenesis and on clinical reports of COVID infection in immunosuppressed patients are used to make a scientifically based decision.


id: cord-274090-eab7i4f6
title: Can Covid‐19 be a sexually transmitted disease? Posterity will judge
author: Gaspari, Valeria
date: 2020-05-24
txt: ./txt/cord-274090-eab7i4f6.txt
cache: ./cache/cord-274090-eab7i4f6.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13676
doi: 10.1111/dth.13676
abstract: nan
summary:
  The knowledge of all possible modes of transmission of SARS-CoV-2 infection is the key to improving both the identification of the asymptomatic population and the necessary isolation measures in order to further flatten the curve. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients (66.67%) has already been demonstrated in recent studies in Wuhan, without being statistically related to gastrointestinal symptoms and/or disease severity. Moreover, the positivity for SARS-CoV-2 on vaginal swab raises the possibility of both sexual and mother-to-child transmission 7 , although further studies are needed on these issues since no definitive proofs have been found. A further step would be adding SARS-CoV-2 serology, pharyngeal, anal and vaginal swabs to our usual STD screening also in the asymptomatic population, in order to identify positive cases and to confirm the SARS-CoV-2 orogenital route of transmission. SARS-CoV-2 possible contamination of genital area: implications for sexual and vertical transmission routes


id: cord-274331-0i2opmcn
title: COVID‐19 infection on IL‐23 inhibition
author: Wang, Catherine J.
date: 2020-07-14
txt: ./txt/cord-274331-0i2opmcn.txt
cache: ./cache/cord-274331-0i2opmcn.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32584451/
doi: 10.1111/dth.13893
abstract: nan
summary:
  Given mild symptoms, the patient was discharged. The patient was discharged 1 week later on home quarantine. The patient in this manuscript has given informed consent to publication of his case details. In our case, the patient recovered from COVID-19 before his next scheduled risankizumab dose. However, more data needs to be obtained about biologics in COVID-19 patients, in particular whether or not biologic dosage timeline should be adjusted based on resolution of infection. A database to collect information on COVID-19 patients on biologic therapy and their outcomes would be instrumental to guide clinicians on best practices for now and in future pandemics. In conclusion, this case illustrates that IL-23 inhibition via biologic therapy in COVID-19 may not correlate with severe respiratory disease. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor


id: cord-277693-6lrawta5
title: Contributions of dermatologists to COVID‐19 research: a brief systematic review
author: Wang, Yuanzhuo
date: 2020-05-30
txt: ./txt/cord-277693-6lrawta5.txt
cache: ./cache/cord-277693-6lrawta5.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13713
doi: 10.1111/dth.13713
summary:
  298 articles were included and classified into cutaneous manifestations of COVID‐19, operating experience against COVID‐19, mechanisms and treatment of COVID‐19, disinfection and personal protective equipment(PPE)‐related skin diseases and other topics. 70 articles focused on cutaneous manifestations of COVID-19 (n=70), followed by the management on patients with common skin diseases (n=68), operating experience against COVID-19 (n=49), mechanisms and treatment of COVID-19 (n=34), disinfection and personal protective equipment(PPE)-related skin diseases (n=27) and other topics(n=50). This study systematically reviewed contributions of dermatologists to COVID-19 research. We hope this study may help dermatologists to have a better understanding of the mechanisms, management, and the cutaneous manifestations of COVID-19, the operating experience of dermatology clinics in the " red-zone" area, and to use disinfectant and personal protective equipment properly. Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times

abstract:
  Coronavirus Disease 2019 (COVID‐19) has been declared a pandemic. We conducted a systematic review to reveal the contribution of dermatologists in COVID‐19 research. 298 articles were included and classified into cutaneous manifestations of COVID‐19, operating experience against COVID‐19, mechanisms and treatment of COVID‐19, disinfection and personal protective equipment(PPE)‐related skin diseases and other topics. The value of these articles and their impact on clinical impact were discussed and we hope that dermatologists can have a better understanding of these areas from this study. This article is protected by copyright. All rights reserved.


id: cord-279056-mmcoqtb5
title: Cutaneous manifestations and considerations in COVID‐19 pandemic: A systematic review
author: Seirafianpour, Farnoosh
date: 2020-07-08
txt: ./txt/cord-279056-mmcoqtb5.txt
cache: ./cache/cord-279056-mmcoqtb5.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13986
doi: 10.1111/dth.13986
summary:
  BACKGROUND: COVID‐19 had a great impact on medical approaches among dermatologist OBJECTIVE: This systematic review focuses on all skin problems related to COVID‐19, including primary and secondary COVID‐related cutaneous presentations and the experts recommendations about dermatological managements especially immunomodulators usage issues METHOD: Search was performed on PubMed, Scopus, Embase and ScienceDirect. Totally 5 article were about skin drug reactions of COVID-19 treatments; two of them were original studies as case reports that were summarized in Table 7 (in the supplement file). In overall, non-infected non-at risk patients with immune-medicated dermatologic disorders under usage of immunosuppressive immunomodulator drugs like biologic agents are not needed to be alter regimen or discontine the therapies during pandemic, even these drugs may control the deteriorating cytokine storms also prevented disease flare-ups which both were associated with poorer outcomes and more complications in COVID-19 course, although strict adherence to quarantine and personal-social preventive hygiene performances are highly recommended especially in these groups of patients.

abstract:
  BACKGROUND: COVID‐19 had a great impact on medical approaches among dermatologist OBJECTIVE: This systematic review focuses on all skin problems related to COVID‐19, including primary and secondary COVID‐related cutaneous presentations and the experts recommendations about dermatological managements especially immunomodulators usage issues METHOD: Search was performed on PubMed, Scopus, Embase and ScienceDirect. Other additional resources were searched included Cochrane, WHO, Medscape and coronavirus dermatology resource of Nottingham university. The search completed on May/03/2020. 377 articles assigned to the inclusion and exclusion groups RESULT: Eighty‐nine articles entered the review. Primary mucocutaneous and appendageal presentations could be the initial or evolving signs of COVID‐19. It could be manifest most commonly as a maculopapular exanthamatous or morbiliform eruption, generalized urticaria or pseudo chilblains recognized as “COVID toes” (pernio‐like acral lesions or vasculopathic rashes). Conclusion: During pandemic, Non‐infected non‐at risk patients with immune‐medicated dermatologic disorders under treatment with immunosuppressive immunomodulators are not needed to alter their regimen or discontinue the therapies. At‐risk and infection‐suspected patients needed to dose reduction, interval increase or temporary drug discontinuation (at least 2 weeks). Patients with an active COVID‐19 infection should hold the biologic or non‐biologic immunosuppressives until the complete recovery occur (at least 4 weeks). This article is protected by copyright. All rights reserved.


id: cord-280774-r2xm164s
title: Management of pernio‐like cutaneous manifestations in children during the outbreak of covid‐19.
author: Gallizzi, Romina
date: 2020-09-19
txt: ./txt/cord-280774-r2xm164s.txt
cache: ./cache/cord-280774-r2xm164s.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32949449/
doi: 10.1111/dth.14312
summary:
  The increased number of cases of pernio-like lesions compared to the cases per year we usually observe, the mild temperatures of those months in Southern Italy and the concomitant lockdown, led us to hypothesize a possible correlation with SARS-CoV-2 infection. This is useful to highlight, as in our case, the D-dimer of our patients was weakly increased, a condition perfectly correlated with the mild symptoms of SARS-CoV-2 putative infection presented. In a report of 19 adolescent patients with a clinical diagnosis of pernio-like lesions nasopharyngeal swab and IgG serology for SARS-CoV-2 nucleocapsid protein were negative. Why some children who come into contact with the SARS-CoV-2 do not develop striking respiratory symptoms but present pernio-like lesions with negativity on diagnostic tests? This pathogenic mechanism could explain the appearance of pernio-like lesions due to SARS-CoV-2 infection. In conclusion, we think there is a correlation between pernio-like lesions and SARS-CoV-2 infection, but further studies are needed to prove it.

abstract:
  BACKGROUND: During the outbreak of COVID‐19 many pernio‐like lesions have been increasingly reported. The aim of the study is to describe our management of these skin manifestations and to evaluate a possible correlation to SARS‐CoV‐2 infection. METHODS: All patients underwent clinical and laboratory tests to detect a possible underlying connective disease and also to specific SARS‐CoV‐2 investigations such as oropharyngeal swab and IgG‐IgM serology. RESULTS: Nine patients aged between five and fifteen years old were evaluated. Skin lesions observed were purplish, erythematous and oedematous, in some cases painful and itchy. Six out of nine had respiratory and systemic symptoms (cough, nasal congestion, chills, fever, asthenia) that preceded cutaneous findings of approximately two weeks. Concerning blood exams, three out of nine had D‐dimer weakly increased, four had ANA positivity: two with a title 1:160, one with 1:320 and one with 1:5120 and a speckled pattern. The latter patient had also ENA SS‐A positive and RF positivity, confirmed at a second check, so as to allow us to make a diagnosis of connective tissue disease. Four out of nine had aPL positivity (IgM). Reactants acute phase were all negative. Oropharyngeal swabs and serology tests for SARS‐CoV‐2 was negative (borderline in one patient for IgM). No treatment was needed. CONCLUSIONS: Even if we do not have enough data to prove it, we hypothesize a correlation between pernio‐like lesions and SARS‐CoV‐2 infection for an increased number of these lesions described during the pandemic and also because such manifestations appeared when temperatures were mild and patients were at home in isolation for the lockdown. Many questions remain open about interaction host‐virus. This article is protected by copyright. All rights reserved.


id: cord-281216-7t647fww
title: Performing dermoscopy in the COVID‐19 pandemic
author: Goldust, Mohamad
date: 2020-05-05
txt: ./txt/cord-281216-7t647fww.txt
cache: ./cache/cord-281216-7t647fww.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32367660/
doi: 10.1111/dth.13506
abstract: nan
summary:
  A novel coronavirus (SARS-CoV-2) that has recently emerged from China in late 2019 has become a global pandemic. Recent data has suggested that SARS -COV2 can remain viable in aerosols for multiple hours. However, cross-infection is a significant concern with contact dermoscopy especially during a viral pandemic. to disinfect hands with 60-70% isopropyl alcohol, provide verbal consents, and wear surgical masks before entering procedure rooms. It is advisable to wear adequate eye protection (goggles or visor) considering that exposed mucous membranes and unprotected eyes can increase the risk of SARS-CoV2 transmission. 4 Mucous membrane dermoscopy should only be performed when the examination has fundamental significance for therapeutic decisions. Aerosol and Surface Stability of SARSCoV-2 as Compared with SARS-CoV-1 Identifying gram-positive cocci on dermatoscopes and smartphone adapters using MALDI-TOF MS: a cross-sectional study 2019-nCoV transmission through the ocular surface must not be ignored


id: cord-284158-5qvq27hu
title: Systemic isotretinoin therapy in the era of COVID‐19
author: Abdelmaksoud, Ayman
date: 2020-05-20
txt: ./txt/cord-284158-5qvq27hu.txt
cache: ./cache/cord-284158-5qvq27hu.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13482
doi: 10.1111/dth.13482
abstract: nan
summary:
  Olfactory epithelium non-neural cell types express two host receptors, ACE2 and type 2 transmembrane serine protease (TMPRSS2), that facilitate SARS-CoV-2 replication and accumulation, and subsequently central nervous system invasion which may lead to respiratory failure of COVID-19 patients. 14 Lechien et al noted that 85.6% of their patients had olfactory dysfunction (79.6% were anosmic and 20.4% were hyposmic) related to COVID-19 infection, with no significant associated rhinorrhea or nasal obstruction. 19 In nutshell, till further studies on the multifaceted pathogenesis of COVID-19 infection, we suggest low, lid-dose of isotretinoin with folic acid supplement, together with proper nasal mucosal care for isotretinoin patients. Isotretinoin treatment should be questioned in all COVID-19 suspected patients presented with nasal/olfactory dysfunction symptoms. Effect of systemic isotretinoin therapy on mucociliary clearance and nasal surface mucosa in acne patients Effects of isotretinoin on the olfactory function in patients with acne


id: cord-287013-9lgg5gya
title: The use of face masks during the COVID‐19 pandemic in Poland: A survey study of 2315 young adults
author: Matusiak, Łukasz
date: 2020-07-13
url: https://doi.org/10.1111/dth.13909
doi: 10.1111/dth.13909
abstract:
  Face masks wearing during the coronavirus disease 2019 (COVID‐19) pandemic became ubiquitous. The aim of our study was to assess the use of face masks among young adults during the current viral pandemic. The survey was based on specially created Google Forms and posted on numerous Facebook groups for young people in Poland. Seven days were considered as a recall period. A total of 2315 answers were obtained, 2307 were finally analysis, as eight questionnaires were removed because of data incompleteness. 60.4% of responders declared using the face masks. Those who reported an atopic predisposition wore face masks significantly (P = .007) more commonly (65.5% and 57.7%, respectively). Cloth masks (46.2%) appeared to be most popular ones, followed by surgical masks (39.2%), respirators (N95 and FFP) (13.3%), half‐face elastomeric respirators (0.8%) and full‐face respirators (0.4%). Females significantly more frequently (P = .0001) used cloth masks; respirators, half‐face elastomeric respirators and full‐face respirators were used more commonly by males (P < .0001, P = .001 and P = .001, respectively). 23.9% of responders who used single‐use mask wore it again. Moreover, 73.6% participants declared mask decontamination; however, the procedures were not always appropriate. We suggest that our results may be of help in construction of general public education campaigns on the proper use of face masks.


id: cord-289819-1kji8bbn
title: Caring for Deaf and Hard of Hearing Patients in Dermatology during the COVID‐19 Pandemic
author: Chang, Michelle J.
date: 2020-08-14
txt: ./txt/cord-289819-1kji8bbn.txt
cache: ./cache/cord-289819-1kji8bbn.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.14185
doi: 10.1111/dth.14185
abstract: nan
summary:
  title: Caring for Deaf and Hard of Hearing Patients in Dermatology during the COVID‐19 Pandemic Safety procedures have been implemented to protect patients and providers, some of which may interfere with effective communication for deaf and hard of hearing (DHH) patients, who already face significant challenges. In this letter, we make recommendations for mitigating communication barriers for DHH dermatological patients during the COVID-19 pandemic. 4 To limit risk of COVID-19 transmission, dermatology practices have dramatically reduced inperson visits and increased utilization of telemedicine and telephone calls, 5 posing significant and unique challenges to DHH patients. If an interpreter is not available for video conferencing, dermatologists should facilitate the encounter via telephone, so that DHH patients may use their preferred telecommunication relay service. The COVID-19 pandemic requires that dermatologists be creative in providing DHH patients with timely and effective care. Overcoming Additional Barriers to Care for Deaf and Hard of Hearing Patients During COVID-19


id: cord-289855-11pkt4uu
title: Employing dermatologists on the frontline against COVID‐19: All hands on deck
author: Bhargava, Shashank
date: 2020-05-13
txt: ./txt/cord-289855-11pkt4uu.txt
cache: ./cache/cord-289855-11pkt4uu.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32297408/
doi: 10.1111/dth.13420
abstract: nan
summary:
  Healthcare providers should be recruited in critical care management depending upon their skill set and confidence level. They should receive training in simple procedures such as vascular access, straightforward intubations, proning maneuvers, and fluid management in uncomplicated patients in order to take off some of the pressure from ICU staff. As the focus shifts from containment efforts to disease mitigation, the healthcare community must step up as a whole to lend its expertise as never before. In a survey among Indian dermatologists, 57% of the respondents would consider redeployment in COVID-19 "hot zones" if a need to augment the medical workforce arises. Our patients need us to move out of our comfort zones and heed the clarion call for "all hands on deck" in order to defeat COVID-19. Strategic planning and recommendations for healthcare workers during the COVID-19 pandemic Our thanks to all healthcare workers on the frontlines caring for our most vulnerable


id: cord-290137-3jyhc63d
author: Szepietowski, Jacek C
date: 2020-06-17
txt: ./txt/cord-290137-3jyhc63d.txt
cache: ./cache/cord-290137-3jyhc63d.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32779845/
doi: 10.1111/dth.13855
abstract: nan
summary:
  During the COVID-19 pandemic health care workers (HCW) have been demonstrated to have higher level of anxiety and depression (1) . (2) suggested that HCW of the departments with high-risk contact with SARS-CoV-2 infected patients demonstrated higher mental health impact. Here, we present our data on mental health status of HCW of two various departments, including university department of dermatology, in Wroclaw, Poland, having different settings. They were asked to fill in the following questionnaires: General Anxiety Disorder -7 (GAD-7), Patient Health Questionnaire -9 (PHQ-9) and Hospital Anxiety and Depression Scale (HADS). Analysing the whole studied group anxiety was suspected among 29.2% (HADS-A) -45% (GAD-7), while depression in 14.2% (HADS-D) -20% (PHQ-9). Anxiety, assessed with HADS-A, and depression, evaluated with PHQ-9, was significantly more prevalent (p<0.01 for both scales) among HCW reporting chronic comorbidities ( Table 2) .

title:
  Mental health status of health care workers during the COVID‐19 outbreak in Poland: one region, two different settings


id: cord-293515-n4v86dii
title: Topical rh‐aFGF: An effective therapeutic agent for facemask wearing‐induced pressure sores
author: Luo, Pan
date: 2020-06-01
txt: ./txt/cord-293515-n4v86dii.txt
cache: ./cache/cord-293515-n4v86dii.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32478959/
doi: 10.1111/dth.13745
summary:
  The results from a small sample size survey conducted in Zhongfaxincheng campuses of Tongji Hospital showed that treatment with topical rh‐aFGF could significantly inhibit the progression of pressure sores and accelerate the wound healing with no apparent ill‐effects. To solve this thorny problem, topical recombinant human acidic fibroblast growth factor (rh-aFGF) was provided to healthcare workers to help curing pressure sores at Zhongfaxincheng campus of Tongji Hospital in Wuhan, China. However, our results from a small sample size survey conducted in the healthcare workers in Zhongfaxincheng campus of Tongji Hospital who have used the topical rh-aFGF with a concentration of 2500 U/ml to cure the stage I/II facemask wearing-induced pressure sores which were less than 1 cm 2 in size show that treatment with topical rh-aFGF could significantly inhibit the progression of pressure sore and accelerate the wound healing.

abstract:
  Protecting healthcare workers is crucial during coronavirus disease 2019 (COVID‐19) pandemic and facemask wearing is considered an effective measure to prevent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. However, long‐time use of a facemask can cause pressure sores on the ears and nose bridge and increase the risk of infection. The topical recombinant human acidic fibroblast growth factor (rh‐aFGF) was used to cure pressure sores for healthcare workers at Zhongfaxincheng campus of Tongji Hospital. The results from a small sample size survey conducted in Zhongfaxincheng campuses of Tongji Hospital showed that treatment with topical rh‐aFGF could significantly inhibit the progression of pressure sores and accelerate the wound healing with no apparent ill‐effects. Therefore, we propose that topical rh‐aFGF is an effective therapeutic agent for facemask wearing‐induced pressure sores and worth of popularizing and applying. This article is protected by copyright. All rights reserved.


id: cord-293711-qgefn164
author: Abdelmaksoud, Ayman
date: 2020-04-16
txt: ./txt/cord-293711-qgefn164.txt
cache: ./cache/cord-293711-qgefn164.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32239587/
doi: 10.1111/dth.13360
abstract: nan
summary:
  apy their recommendations for treatment of patients with psoriasis at time of new COVID-19 pandemic. The authors pointed to the importance of therapeutic reassessment of all psoriatic patients, particularly those with moderate-to-severe disease, who are candidate to systemic, mostly immunosuppressive, therapies in the era of COVID-19. COVID-19 virus has neurotropic potential that partially explains the higher rate of acute respiratory distress in elderly patients. ultraviolet A1 (UVA1) phototherapy has a comparable efficacy in moderate-to-severe plaque-type psoriasis and could improve the clinical manifestations and quality of life more quickly than narrow band ultraviolet B therapy with no significant side effects, including lack of increased risk of cutaneous malignancies. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? Older adults on systemic treatment for psoriasis and risk of infection:a propensity score matched population-based study Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis Should patients stop their biologic treatment during the COVID-19 pandemic

title:
  Comment on “COVID‐19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action”


id: cord-295995-uabnyomr
title: Sexually Transmitted COVID19
author: Abdelmaksoud, Ayman
date: 2020-07-08
txt: ./txt/cord-295995-uabnyomr.txt
cache: ./cache/cord-295995-uabnyomr.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13982
doi: 10.1111/dth.13982
abstract: nan
summary:
  key: cord-295995-uabnyomr cord_uid: uabnyomr In their study on healthy women, Yuksel and Ozgor found a significant higher sexual desire and frequencies of sexual intercourse during COVID19 pandemic compared with 6-12 months prior. 4 on 10 severely infected women with COVID-19, no SARS-CoV-2 virus was noted in their vaginal fluids. They concluded that likelihood of transmitting SARS-Cov-2 to sexual partners through vaginal fluids may be low. 5 Genital contamination with genital fluids, even with low rate, is not unexpected. Due to risk of "genital" contamination with SARSThis article is protected by copyright. They are at risk of not only STDs, but also SARS-CoV2 through genital contamination. COVID19 patients presented with PR, or known STD, should be enquired about their sexual behavior/preference, and should undergo more than a nasopharyngeal swab before considering negativity of infection. Can Covid-19 Be a Sexually Transmitted Disease? Effect of the COVID-19 Pandemic on Female Sexual Behavior SARS-CoV-2 Is Not Detectable in the Vaginal Fluid of Women With Severe COVID-19 Infection


id: cord-296022-yl3j2x5p
title: COVID‐19 and economy
author: Gupta, Mrinal
date: 2020-04-08
txt: ./txt/cord-296022-yl3j2x5p.txt
cache: ./cache/cord-296022-yl3j2x5p.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13329
doi: 10.1111/dth.13329
abstract: nan
summary:
  key: cord-296022-yl3j2x5p cord_uid: yl3j2x5p concern, COVID-19 is having major consequences on the world economy, and experts have predicted that COVID-19 will lower global gross domestic product growth by one-half a percentage point for 2020 (from 2.9% to 2.4%). The whole world is now a single global community, where any major happening in one part is bound to have repercussions in rest of the world. 2 Chinese government, in order to control the spread of the disease, had to close the major production centers and as China being a manufacturing hub, led to disruption in the global supply chain which affected almost all sectors ranging from pharmaceuticals to automobile. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19) How is the world responding to the 2019 coronavirus disease compared with the 2014 west African Ebola epidemic? The importance of China as a player in the global economy The global macroeconomic impacts of COVID-19: Seven scenarios


id: cord-296128-kjoi54ea
author: Balestri, Riccardo
date: 2020-08-26
txt: ./txt/cord-296128-kjoi54ea.txt
cache: ./cache/cord-296128-kjoi54ea.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32844512/
doi: 10.1111/dth.14229
summary:
  Our review demonstrated a high prevalence of negative serological results in CLL: antibodies were observed only in a few patients, that are even less excluding those with positive IgA, not clearly involved in the pathogenesis of the disease. The outbreak of chilblain-like lesions (CLL) coincidentally to the COVID-19 pandemic is a topic of great concern 1 SARS-CoV-2 was hypothesized as the etiologic agent of CLL, initially on the basis of the temporal correlation between the "burst" of skin manifestations and the viral pandemic. However, it has been shown that CLL are not related to an acute infection, since real-time reverse transcription polymerase chain reaction (rt-PCR) tests from nasopharyngeal swabs seldom resulted positive 1-9Therefore, dermatologists'' attention shifted to the search for specific SARS-CoV-2 antibodies. The search was limited to articles published in English We included only case series, clearly declaring that a search for SARS-CoV-2 specific antibodies had been performed. Chilblain-like lesions during COVID-19 pandemic: a serological study on a case series

title:
  Do we have serological evidences that chilblain‐like lesions are related to SARS‐CoV‐2? A review of the literature

abstract:
  The outbreak of chilblain‐like lesions (CLL) coincidentally to the COVID‐19 pandemic is a topic of great concern. SARS‐CoV‐2 was initially hypothesized as the etiologic agent of CLL, but, since nasopharyngeal swabs seldom resulted positive, dermatologists’ attention focused on the search for specific SARS‐CoV‐2 antibodies. Many papers were published contemporarily on this topic, reporting limited case series. We reviewed the English literature up to the 1(st) July 2020 and, excluding single case reports, we considered 13 studies that serologically investigated 220 patients. The presence of specific antibodies was detected in 18 subjects (8,2%): isolated IgA were found in 6 patients, IgA and IgG in 1, isolated IgG in 5, and IgM in 2. In 4 patients, isotypes were not specified. Our review demonstrated a high prevalence of negative serological results in CLL: antibodies were observed only in a few patients, that are even less excluding those with positive IgA, not clearly involved in the pathogenesis of the disease. In conclusion, although it is still uncertain whether CLL are related to SARS‐CoV‐2 infection, patients affected by CLL seem not to be prone to shedding the virus, hence, if they are asymptomatic, we can reassure them, thus avoiding hospital referral This article is protected by copyright. All rights reserved.


id: cord-297295-lsewt5t2
author: Matusiak, Łukasz
date: 2020-05-14
txt: ./txt/cord-297295-lsewt5t2.txt
cache: ./cache/cord-297295-lsewt5t2.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13567
doi: 10.1111/dth.13567
abstract: nan
summary:
  title: Inconveniences due to the use of face masks during the COVID‐19 pandemic: a survey study of 876 young people Personal protective equipment (PPE) can cause harm to the skin (2) (3) (4) (5) , however, little is known on inconveniences of face masks wearing (4) (5) (6) (7) . Interestingly, other skin bothersome reactions related to wearing of face masks were reported less often (itch -7.7%, skin irritation -0.9%). In the model of logistic regression analysis we found that wearing surgical masks among the other types of masks showed significantly lower risk for the development of most common bothersome issues, as difficulty in breathing, warming/sweating, glasses misting up, slurred This article is protected by copyright. In contrast, cloth masks use was related to higher risk of difficulty in breathing (OR=1.56), warming/sweating (OR=1.31), glasses misting up (OR=1.92), slurred speech (OR=1.86) and itch (OR=2.99).

title:
  Inconveniences due to the use of face masks during the COVID‐19 pandemic: a survey study of 876 young people


id: cord-297400-l8fhy1hu
title: A case of dermatitis artefacta during a pandemic
author: Adebanjo, Ganiyat Adenike Ralitsa
date: 2020-08-26
txt: ./txt/cord-297400-l8fhy1hu.txt
cache: ./cache/cord-297400-l8fhy1hu.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.14235
doi: 10.1111/dth.14235
abstract: nan
summary:
  A 68-year-old woman, who had been affected by mood and anxiety disorders for many years, presented during the COVID-19 lockdown period with self-inflicted skin lesions on several part of the body. There is a plethora of skin lesions which may be associated to dermatitis artefacta and they are often endowed with non-specific pathophysiological findings 5 as in the case of our patient. On the other hand, dermatitis artefacta is usually associated to lesions which are heterogeneous in appearance and that are produced to fulfill a subconscious need to be seen as vulnerable 9 : in this case the pruritus is a consequence of the disease and not a preceding factor. We decided to report this case because in this patient dermatitis artefacta seems to be related to and appeared in coincidence with the COVID-19 emergency and lockdown.


id: cord-299681-smhto9em
title: Herpes zoster might be an indicator for Latent COVID 19 infection
author: Elsaie, Mohamed L.
date: 2020-05-23
txt: ./txt/cord-299681-smhto9em.txt
cache: ./cache/cord-299681-smhto9em.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13666
doi: 10.1111/dth.13666
summary:
  In this report we describe two cases COVID infection who first presented with herpes zoster. We are here by suggesting that the clinical presentation of HZ at the time of the current pandemic even in patients giving mild or no suggestive history of upper respiratory symptoms should be considered as an alarming sign for a recent subclinical SARS CoV2 infection. Most patients with COVID-19 exhibit mild to moderate symptoms, but approximately 15% of the cases progress to severe pneumonia and about 5% eventually develop acute respiratory distress syndrome (ARDS), septic shock and/or multiple organ failure (3, 4) . We present two cases of clinically diagnosed Herpes zoster infection attending two different clinics, both patients'' showed no or mild symptoms of COVID 19 infection and denied any history of contact with known or suspected COVID19 cases. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

abstract:
  Various cutaneous manifestations have been observed in patients with COVID‐19 infection. Herpes Zoster is a viral skin disease caused by varicella zoster that remains dormant in the dorsal root ganglia of cutaneous nerves following a primary chicken pox infection. In this report we describe two cases COVID infection who first presented with herpes zoster. We are here by suggesting that the clinical presentation of HZ at the time of the current pandemic even in patients giving mild or no suggestive history of upper respiratory symptoms should be considered as an alarming sign for a recent subclinical SARS CoV2 infection. This article is protected by copyright. All rights reserved.


id: cord-301107-0njnjqeb
title: The Clinics of HHV‐6 infection in COVID‐19 pandemic: Pityriasis rosea and Kawasaki disease
author: Dursun, Recep
date: 2020-05-31
txt: ./txt/cord-301107-0njnjqeb.txt
cache: ./cache/cord-301107-0njnjqeb.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32475003/
doi: 10.1111/dth.13730
summary:
  After pandemic, the number of patients with Pityriasis rosea and Kawasaki disease increased significantly in patients who applied to the dermatology outpatient clinic. Herein, we wanted to aim to evaluate whether two diseases (Pityriasis rosea and Kawasaki disease), in which Human Herpesvirus 6 (HHV-6) was held responsible for etiopathogenesis, after the COVID-19 pandemic. After pandemic, the number of patients with Pityriasis rosea increased significantly in patients who applied to the dermatology outpatient clinic (p:0,000). After pandemic, the number of patients with Kawasaki disease increased significantly in patients who applied to the dermatology outpatient clinic (p:0,009). In our study, it was found that the rate of Pityriasis rosae patients who applied to the dermatology outpatient clinic this year during the pandemic period increased approximately 5 times compared to the same time last year. In our study, there was a 10-fold increase in the rate of patients with Kawasaki disease who applied to the dermatology outpatient clinic compared to the previous year.

abstract:
  A new type of coronavirus family (SARS‐CoV‐2), which can be found in humans and animals, with many varieties and clinical symptoms, was first seen in Wuhan, China in late 2019, under the name novel Coronavirus Disease 2019 (COVID‐19). In the literature, cutaneous symptoms related to the disease are generally emphasized. However, it is not yet known whether this new SARS‐CoV‐2 virus, which has entered our lives, plays a role in the etiopathogenesis of dermatological diseases. The patients who were admitted to the dermatology outpatient clinic between 1 April and May 15, 2019, and on 1 April and May 15, 2020 were retrospectively analyzed by searching the hospital automation system and patient files. The reason for the same months to be included in the study was to exclude seasonal effects on the diseases. After pandemic, the number of patients with Pityriasis rosea and Kawasaki disease increased significantly in patients who applied to the dermatology outpatient clinic. Our study is the first study showing pityriasis rosea increase during the pandemic period. We think that this increase is related to HHV‐6 reactivation. Herein, we wanted to draw attention to two diseases in which Human Herpes 6 (HHV‐6) was accused in etiopathogenesis: Kawasaki disease and Pityriasis rosea. This article is protected by copyright. All rights reserved.


id: cord-302571-vb9ks4mq
author: Damiani, Giovanni
date: 2020-05-19
txt: ./txt/cord-302571-vb9ks4mq.txt
cache: ./cache/cord-302571-vb9ks4mq.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32356577/
doi: 10.1111/dth.13475
summary:
  title: Biologics increase the risk of SARS‐CoV‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration With respect to the general population of Lombardy, patients on biologics were at higher risk to test positive for COVID‐19 (odds ratio [OR] 3.43 [95% confidence interval (CI) 2.25‐5.73], P < .0001), to be self‐quarantined at home (OR 9.05 [95% CI 5.61‐14.61], P < .0001) and hospitalized (OR 3.59 [95% CI 1.49‐8.63], P = .0044), however, not increased risk of ICU admission or death were found. PsO patients on biologics displayed higher risk to be infected and to be hospitalized/self-quarantined at home, but ICU hospitalization and death did not differ from the general population. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration

title:
  Biologics increase the risk of SARS‐CoV‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

abstract:
  During COVID‐19 outbreak there are discordant opinions toward the impact on biologics in psoriatic (PsO) patients. Thus we performed a single‐center case‐control study in Lombardia, the Italian region with the higher number of COVID‐19 confirmed cases. We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID‐19 confirmed were quarantined at home and five hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to test positive for COVID‐19 (odds ratio [OR] 3.43 [95% confidence interval (CI) 2.25‐5.73], P < .0001), to be self‐quarantined at home (OR 9.05 [95% CI 5.61‐14.61], P < .0001) and hospitalized (OR 3.59 [95% CI 1.49‐8.63], P = .0044), however, not increased risk of ICU admission or death were found. PsO patients on biologics should be carefully monitored with telemedicine during COVID‐19 outbreak and early treated at home to limit hospital overwhelm.


id: cord-302676-aarcjyia
title: Where do we stand as dermatologists in combat with COVID‐19
author: Goldust, Mohamad
date: 2020-05-22
txt: ./txt/cord-302676-aarcjyia.txt
cache: ./cache/cord-302676-aarcjyia.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13638
doi: 10.1111/dth.13638
abstract: nan
summary:
  The novel corona virus disease (COVID-19 due to SARS-CoV-2) which began in Wuhan, China in late December 2019, quickly spread to involve the rest of the world within a span of few weeks. [1] [2] [3] Hygiene measures are of paramount importance to combat transmission of COVID-19 including social distancing, meticulous hand hygiene measures like frequent hand washing, avoiding touching the face and wearing masks. Healthcare workers, who are at high risk of acquiring the infection are advised to wear personal protective equipment (PPE). aggravate during periods of stress, like psoriasis, eczema, atopy and neurodermatitis can also flare up either in health care workers or in patients. The patient presented with petechiae rash and lab reports showed thrombocytopenia, the two common features of dengue. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Personal Protective Equipment: An Emerging Issue in the COVID-19 Pandemic


id: cord-303460-abutfxtf
title: Screen rhytides: the cosmetic legacy of COVID‐19
author: Searle, Tamara
date: 2020-08-21
txt: ./txt/cord-303460-abutfxtf.txt
cache: ./cache/cord-303460-abutfxtf.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.14211
doi: 10.1111/dth.14211
abstract: nan
summary:
  key: cord-303460-abutfxtf authors: Searle, Tamara; Ali, Faisal R.; Al‐Niaimi, Firas title: Screen rhytides: the cosmetic legacy of COVID‐19 date: 2020-08-21 journal: Dermatol Ther cord_uid: abutfxtf contraction may reduce the length of time that botulinum toxin exerts its effects, resulting in an increased demand for more sessions of botulinum toxin with shorter intervals between each treatment. The authors are observing a sharp increase and awareness of glabellar and lateral canthal lines with patients directly referring the effects to increased "screen activity". Emerging reports of patients self-administering botulinum toxin with black-market at home kits demonstrates some patients'' desperation, with devastating potential adverse effects. 3 COVID-19 lockdown restrictions necessarily prohibited access to most aesthetic injectable treatments and as cosmetic clinics start to reopen, cosmetic dermatologists are likely to have a backlog of patients. 4 We suggest cosmetic practitioners should assess for and treat wrinkles and other facial changes resulting from prolonged screen activities.


id: cord-305076-v56y5nyt
author: Singh, Parmvir
date: 2020-07-23
txt: ./txt/cord-305076-v56y5nyt.txt
cache: ./cache/cord-305076-v56y5nyt.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32700813/
doi: 10.1111/dth.14053
summary:
  Clinical patterns with DIC are varied, exemplified by those identified with COVID-19, from petechial to acro-ischemia presentations including finger/toe cyanosis, skin bulla and dry gangrene, some resembling chilblains disease (Figures 1,2) 7 . 8, 15 Skin manifestations caused by thrombosis include acral cyanosis (25%) and gangrene (17%). 8 It is important to differentiate the thrombotic/coagulopathic vasculopathic acral ischemia as seen in DIC from chilblain-like lesions (blue "COVID toes"), also associated with the This article is protected by copyright. 1,24,43-46 COVID-19-associated DIC therapy should follow accepted strategy employing thromboembolic prophylaxis for critically ill hospitalized patients and standard supportive care measures 47 . Presentation and outcome of purpura fulminans associated with peripheral gangrene in 12 patients at Mayo Clinic Comparison of a new criteria for sepsis-induced coagulopathy and International Society on Thrombosis and Haemostasis disseminated intravascular coagulation score in critically ill patients with sepsis 3.0: a retrospective study

title:
  Disseminated Intravascular Coagulation: A Devastating Systemic Disorder of Special Concern with COVID‐19

abstract:
  Disseminated intravascular coagulation (DIC) is linked with severe COVID‐19, prompting considerable concern. DIC can be a devastating systemic disorder. It is often markedly manifest on the skin as acrocyanosis or as petechiae and purpura with progression to hemorrhagic bullae. Subcutaneous hematomas may occur, as may thrombotic findings including necrosis and gangrene. This article is protected by copyright. All rights reserved.


id: cord-305966-a61v2615
title: CD147 inhibitors as a treatment for melanoma: promising agents against SARS‐CoV‐2 infection
author: Pourani, Mohammad Reza
date: 2020-10-24
txt: ./txt/cord-305966-a61v2615.txt
cache: ./cache/cord-305966-a61v2615.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/33098610/
doi: 10.1111/dth.14449
abstract: nan
summary:
  1 The CD147 protein (known as basigin) is a transmembrane protein that has recently been suggested as a potential receptor for SARS-CoV-2. 2 Recent studies have reported that the spike protein of SARS-CoV-2 attaches to host cells via angiotensin-converting enzyme-2 (ACE-2) and CD147 receptors. 3 In fact, recent studies have suggested CD147 as a novel tumor marker in the early diagnosis of some cancers like head and neck squamous cell carcinoma and hepatocellular carcinoma. 8 In conclusion, considering the possible role of CD147 in the pathogenesis of COVID-19, CD147 inhibitors may be considered as promising treatments for SARS-CoV-2 infection. CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement CD147-targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression FDA approved drugs with pharmacotherapeutic potential for SARS CoV-2 (COVID-19) therapy


id: cord-306070-2dgs5oih
title: Cutaneous manifestations in hospitalized patients diagnosed as COVID‐19
author: Askin, Ozge
date: 2020-06-24
txt: ./txt/cord-306070-2dgs5oih.txt
cache: ./cache/cord-306070-2dgs5oih.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32579756/
doi: 10.1111/dth.13896
summary:
  According the statistical results the patients who were hospitalized in the intensive care unit had a higher risk of having cutaneous findings due to COVID‐19 infection. During this pandemic, several case reports, and some articles were published about cutaneous manifestations of COVID-19 infection. Comparison of cutaneus manifestations according to variables of hospitalization (ward vs intensive care unit), age, gender, RT-PCR result was performed using chi-square independence test. The relationship between PCR positivity and cutaneous findings was examined by chi-square independence test and no statistical relationship was obtained between them ( χ 2 =1.990; sd=1; p>0.05) ( Table 3) . It was determined that the patients who were hospitalized in the ICU had a higher risk of having cutaneous findings due to COVID-19 infection (Table 5) . In our study 24% of the patients who were hospitalized showed cutaneous findings during COVID-19 infection.

abstract:
  BACKGROUND: Cutaneous manifestations of COVID‐19 disease have not yet been fully described. OBJECTIVES: To describe cutaneous manifestations of COVID‐19 disease in hospitalized patients. METHODS: We examined the cutaneous manifestations of 210 hospitalized patients. RESULTS: Cutaneous findings were observed during COVID‐19 infection in 52 of the patients. Lesions may be classified as erythematous scaly rash (32.7%), maculopapular rash (23%), urticarial lesions (13.5%), petechial purpuric rash (7.7%), necrosis (7.7%), enanthema and apthous stomatitis (5.8%), vesicular rash (5.8%), pernio (1.9%) and pruritus (1.9%). Cutaneous manifestations were observed statistically significantly more in certain age groups: patients of 55 to 64 and 65 to 74 years of age complained of more cutaneous manifestations than the other age groups. As for gender, there was no significant difference between male and female patients in terms of cutaneus findings. The relationship between comorbidity and dermatological finding status was statistically significant. The relationship increases linearly according to the comorbidities. According the statistical results the patients who were hospitalized in the intensive care unit had a higher risk of having cutaneous findings due to COVID‐19 infection. CONCLUSIONS: With this study we may highlight the importance of overlooked dermatological findings in patients that are hospitalized. This article is protected by copyright. All rights reserved.


id: cord-307000-mc5tpnbj
title: Management of patients with Hidradenitis Suppurativa during the COVID‐19 pandemic
author: Montero‐Vilchez, T
date: 2020-06-19
txt: ./txt/cord-307000-mc5tpnbj.txt
cache: ./cache/cord-307000-mc5tpnbj.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13875
doi: 10.1111/dth.13875
abstract: nan
summary:
  Adults and children with HS are at higher risk of cutaneous, extracutaneous and systemic infections, at even higher rates than in patients with psoriasis and atopic dermatitis, which leads to increased mortality 3 . In the most severe COVID-19 cases, the infection is probably associated with a cytokine storm, which is characterized by increased This article is protected by copyright. Although there are no reports on HS treatment during the COVID-19 pandemic or a previous coronavirus epidemic, the guidelines do not recommend stopping treatment due to potential infection risks in the community. Therefore, while there is no evidence that biologics increase the risk or morbidity of a COVID-19 infection, we should not recommend preventively discontinuing these medications. Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations Should patients stop their biologic treatment during the COVID-19 pandemic


id: cord-307925-0nhsf90c
title: Dupilumab in atopic dermatitis, a protocol for SARS‐COV 2 infected patients
author: Ordóñez‐Rubiano, Maria Fernanda
date: 2020-08-10
txt: ./txt/cord-307925-0nhsf90c.txt
cache: ./cache/cord-307925-0nhsf90c.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32779378/
doi: 10.1111/dth.14172
abstract: nan
summary:
  During SARS-COV 2 pandemic scarce articles have been written regarding the possible effects of biologics and immunosuppressants in chronic inflammatory skin diseases, such as atopic dermatitis (AD) 1 . Therefore, it is important as dermatologist to be involved in health care of infected or COVID-19 patients having severe dermatological diseases and making appropriate decisions for their skin health. On May 18th, 2020 he was diagnosed with asymptomatic SARS-COV 2 by PCR due to occupational exposure, to our knowledge the first patient in Latin America infected while in treatment with dupilumab. SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab European Task Force on Atopic Dermatitis (ETFAD) statement on severe This article is protected by copyright. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single center real-life experience Figure 1: Protocol for atopic dermatitis In patients treated with dupilumab This article is protected by copyright.


id: cord-309195-0scmephx
title: Hand eczema ‐ a growing dermatological concern during the COVID‐19 pandemic and possible treatments
author: Blicharz, Leszek
date: 2020-05-08
txt: ./txt/cord-309195-0scmephx.txt
cache: ./cache/cord-309195-0scmephx.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32384196/
doi: 10.1111/dth.13545
abstract: nan
summary:
  title: Hand eczema ‐ a growing dermatological concern during the COVID‐19 pandemic and possible treatments 3 Regardless of HE etiology, exposure to detergents and soaps, frequent hand washing (>20 times/day) and the use of occlusive gloves are all well-known risk factors of disease onset This article is protected by copyright. Topical steroids such as clobetasol propionate and mometasone furoate are usually the first-choice anti-inflammatory agents, though they may interfere with the skin barrier regeneration and thus their long-term This article is protected by copyright. 6 Lastly, systemic agents should be considered in severe cases refractory to topical treatment. Therapeutic options include short courses of systemic steroids during disease exacerbations, oral retinoids, e.g. alitretinoin, acitretin, and immunosuppressants such as methotrexate, azathioprine, and cyclosporine A. 6 Despite the lack of evidence on the increased risk of severe COVID-19 in immunocompromised patients, 7, 8 we believe that the first-line systemic treatment should involve oral retinoids followed by immunosuppressants in recalcitrant cases. Hand eczema: treatment


id: cord-309813-qojacnli
title: Recommendations for Diagnosis and Treatment of Onychomycosis During the COVID‐19 Pandemic
author: Lipner, Shari R.
date: 2020-05-30
txt: ./txt/cord-309813-qojacnli.txt
cache: ./cache/cord-309813-qojacnli.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32474984/
doi: 10.1111/dth.13709
abstract: nan
summary:
  1 Prior to the COVID-19 pandemic, clinical examination, dermoscopy, and mycological examination were recommended for all patients with suspected onychomycosis, followed by a discussion of appropriate treatment options. 2 However, with prevalence of COVID-19, non-urgent inperson visits are deferred, and telemedicine may be utilized to address some aspects of onychomycosis diagnosis and treatment. Onychomycosis treatment guidelines prior to the COVID-19 pandemic are no longer applicable. Telemedicine can be used for initial consultation of patients with onychodystrophy and topicals prescribed for tinea pedis if indicated; patients with confirmed onychomycosis can be monitored for clear nail growth and side effects. Confirmatory Testing Prior to Initiating Onychomycosis Therapy Is Cost-Effective Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration Retrospective Analysis of Laboratory Abnormalities in Patients Prescribed Terbinafine for Onychomycosis


id: cord-312331-k87js3aw
title: New data about sexually transmitted COVID‐19
author: Tatu, Alin Laurentiu
date: 2020-11-01
txt: ./txt/cord-312331-k87js3aw.txt
cache: ./cache/cord-312331-k87js3aw.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.14426
doi: 10.1111/dth.14426
abstract: nan
summary:
  4 We also propose that close contact between partners might be a risk for viral transmission as the lipid envelope that encapsulates the coronavirus could allow it to be stable in areas with high sebum production such as on the hair of the scalp, eyelashes, ears, or beard. To date, real-time polymerase chain reaction assays from the vesicular fluid of suspected SARS-CoV-2 vesicles have been unable to demonstrate viral RNA, but current data are limited to only four patients and the study notes a lack of assay standardization and a low viral load as possible sources of error. 9 Bearing this in mind, we recommend that patients who present with a possible viral exanthem related to the SARS-CoV-2 refrain from close contact with others, and in such circumstances the recommendation of sexual abstinence would be appropriate. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? Observations about sexual and other routes of SARS-CoV-2 (COVID-19) transmission and its prevention


id: cord-315166-ga6e3lqp
author: Isoletta, Eugenio
date: 2020-07-18
txt: ./txt/cord-315166-ga6e3lqp.txt
cache: ./cache/cord-315166-ga6e3lqp.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32681752/
doi: 10.1111/dth.14027
summary:
  Since February 21 st , 2020, when the first case in Italy was confirmed, an overwhelming number of SARS-CoV-2 infections were detected and hospital organizations have adapted to cope with the emergency, 1,2 . We performed a retrospective review of all dermatological consultations in the ED of IRCSS San Matteo between February 22 nd (date of the first proven autochthonous Covid-19 case) and May 3 rd (date of the end of the "phase 1" of the lockdown). Our aim was to evaluate the impact of the ongoing pandemic on the number of dermatological ED consultation, on the severity of cases presented to the ED with cutaneous symptoms, and on the diagnoses at discharge. The first finding emerging from our data was a dramatic reduction in the request for dermatological ED consultations during the COVID pandemic comparing to the same period in 2019, from 164 patients to 33, with an absolute difference of -79.9 percentage points ( Table 1 ).

title:
  Emergency accesses in Dermatology Department during the Covid‐19 pandemic in a referral third level center in the north of Italy

abstract:
  During the lockdown period most planned visits have been postponed and the number of accesses to Emergency Department (ED) has dramatically reduced. The aim of our study is to analyze the impact of the lockdown on the number, type and severity of Dermatological ED diagnosis. We performed a retrospective review of all dermatological consultations in the ED of IRCSS San Matteo during the lockdown period in Italy (February 22nd ‐ May third 2020) and compared them with those from the same period in 2019. We noticed a sharply reduction in the number of dermatological consultations requested in the ED: from 164 patients in 2019 to 33 in 2020. Some diagnostic categories showed a significant difference with a higher incidence of vasculopathic lesions (0.6% vs 12.1%, P < 0.0001), urticarial rashes (8.5% vs 21.2%, P = 0.03) and scabies (3% vs 12.1%, P = 0.023). We observed an increase in the proportion of patients starting medications, before coming to the ED 26.2% in 2019 vs 66.7% in 2020 (P < 0.001). Furthermore, we noticed a significant increase in the average complexity of cases presenting to the ED in 2020, as proven by the increased need for biopsies and systemic therapy. This article is protected by copyright. All rights reserved.


id: cord-317323-wp3vh4c1
title: The changing paradigm of an aesthetic practice during the COVID‐19 pandemic: An expert consensus
author: Kandhari, Rajat
date: 2020-10-28
txt: ./txt/cord-317323-wp3vh4c1.txt
cache: ./cache/cord-317323-wp3vh4c1.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/33090637/
doi: 10.1111/dth.14382
summary:
  It is pertinent that the physician today understands the infection, disinfection measures, and personal protective equipment to reduce chances of viral transmission and provide safe clinical settings for oneself, the staff and the patients. While certain guidelines and expert consensus have recently been published [2] [3] [4] providing an overview of "safe" working protocols, it appears that we are evolving every day in our practices with respect to "what works" and "what does not." Our article aims to bridge the gap between guidelines and in-clinic experiences to provide a set of best practices to follow for aesthetic procedures after reopening our practices. In contrast, the occurrence of airborne transmission is due to smaller particles, which maybe suspended in the air for long periods and can infect people distant from the source (eg, AGP''s)PPE consists of protective apparel and/or equipment designed for providing protection against infectious agents to HCW''s and their patients. Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings

abstract:
  Until vaccination for the SARS‐CoV‐2 becomes a reality, it appears that the infection is here to stay. With many countries lifting lockdown restrictions, aesthetic clinics have started reopening with strict standard operating procedures in place. It is pertinent that the physician today understands the infection, disinfection measures, and personal protective equipment to reduce chances of viral transmission and provide safe clinical settings for oneself, the staff and the patients. An online meeting of eight experts in the field of aesthetic dermatology was convened, which particularly focussed on PPE in detail, risk categorization of aesthetic procedures, preprocedure recommendations, and generalized and specialized SOP's for aesthetic procedures. These recommendations were aimed to bridge the gap between published guidelines and clinical practice and are by no means fully conclusive, but signify learnings over the past few months in an active clinical aesthetic practice.


id: cord-318866-3arxrm8m
author: Magnano, M.
date: 2020-05-30
txt: ./txt/cord-318866-3arxrm8m.txt
cache: ./cache/cord-318866-3arxrm8m.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13706
doi: 10.1111/dth.13706
abstract: nan
summary:
  The management of psoriatic patients under biologics during SARS-CoV-2 outbreak is of great concern, as well as the outcome of the COronaVirus DIsease (COVID-19) in this population. On a pool of 720 psoriatic patients followed by our 3 referral centers for severe psoriasis, we registered 9 swab-confirmed cases of SARS-CoV-2 infection (Table 1) . 1 , who concluded that, despite the cardiovascular and metabolic comorbidities affecting psoriatic patients and also representing risk factors for severe COVID-19, patients seldom required hospitalization. 2 The appropriateness of withdrawing biologic therapies preventively in psoriatic patients is still debated and it is also unclear whether their use influences the course of COVID-19 or not. 4 The psoriatic population treated with biologic therapies is on average young 5 , since elderly patients with multiple comorbidities are usually excluded from systemic treatments. Although this case series is limited, we evidenced that ARDS can represent a complication also in patients under biologics.

title:
  Psoriasis, COVID‐19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment


id: cord-319820-eb5y7gxj
author: Kutlu, Ömer
date: 2020-07-02
txt: ./txt/cord-319820-eb5y7gxj.txt
cache: ./cache/cord-319820-eb5y7gxj.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13949
doi: 10.1111/dth.13949
summary:
  The terms "acne", "hair loss", "eczema", "genital warts", "molluscum contagiosum", "botox", "skin cancer", "sunscreen" were analyzed on first April, first May, first June 2020, and the corresponding period of the previous year in Turkey and Italy by using Google Trends. The relative change of search term "acne" was +10, +29, +13/ ‐1, +17,+33, "hair loss" was +14, +40, +16/+3, +16, +15, and "eczema" was +2, +34, −4/ +3, +25, +18, on the other hand, the relative change of the "genital warts" was −15, −48, +10/ ‐44, −30, +18 and "molluscum contagiosum" was −12, −2, −4/ ‐4, −1, −12 while "botox" was, −10, −43, −8/ ‐41, −31, +4, "skin cancer" was −27, −38, −38/−22,+33, −7 and sunscreen was −6, −25, −71/−13,0,‐45 in Turkey/Italy on 1 st April, 1 st May, and 1 st June, 2020, respectively. The search terms including "acne", "eczema", "hair loss" appears to be increasing while "molluscum contagiosum", "genital warts" "botox", "skin cancer", and "sunscreen" decreasing in the era of the COVID‐19 pandemic.

title:
  Analysis of dermatologic conditions in Turkey and Italy by using Google Trends analysis in the era of the COVID‐19 pandemic

abstract:
  Many areas of life including patterns of dermatological diseases that patient attend to the hospital were tremendously affected by implementing stay‐at‐home orders during the COVID‐19 pandemic. We aimed to identify the dermatologic interest of the public during the COVID‐19 pandemic by using Google Trends. The terms “acne”, “hair loss”, “eczema”, “genital warts”, “molluscum contagiosum”, “botox”, “skin cancer”, “sunscreen” were analyzed on first April, first May, first June 2020, and the corresponding period of the previous year in Turkey and Italy by using Google Trends. The searching spectrum was between 3first March 2019‐first June 2020. The relative change of search term “acne” was +10, +29, +13/ ‐1, +17,+33, “hair loss” was +14, +40, +16/+3, +16, +15, and “eczema” was +2, +34, −4/ +3, +25, +18, on the other hand, the relative change of the “genital warts” was −15, −48, +10/ ‐44, −30, +18 and “molluscum contagiosum” was −12, −2, −4/ ‐4, −1, −12 while “botox” was, −10, −43, −8/ ‐41, −31, +4, “skin cancer” was −27, −38, −38/−22,+33, −7 and sunscreen was −6, −25, −71/−13,0,‐45 in Turkey/Italy on 1 st April, 1 st May, and 1 st June, 2020, respectively. A statistically significant positive correlation was found between the number of COVID‐19 cases in Turkey and search terms of the general dermatology group during the COVID‐19 pandemic (P < 0.05). The search terms including “acne”, “eczema”, “hair loss” appears to be increasing while “molluscum contagiosum”, “genital warts” “botox”, “skin cancer”, and “sunscreen” decreasing in the era of the COVID‐19 pandemic. Understanding the trends and impacts of dermatologic diseases on public perceptions during the COVID‐19 pandemic will allow for better preparation of dermatologists. This article is protected by copyright. All rights reserved.


id: cord-320862-ua69gcxv
author: Giacalone, Serena
date: 2020-05-20
txt: ./txt/cord-320862-ua69gcxv.txt
cache: ./cache/cord-320862-ua69gcxv.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13630
doi: 10.1111/dth.13630
abstract: nan
summary:
  The Center for Disease Control and prevention (CDC) asserted that hand washing and surface decontamination are primary measures to reduce COVID-19 propagation [1] . In parallel, recent studies revealed an increased incidence of hand eczema (HE) in health care workers [2] , as well as among general population [3] . The remaining ten patients were suggested two or three daily applications of reparative hand cream This article is protected by copyright. Above all, we focused our attention on giving information about rational of hand hygiene and preventing clinical relapses with daily application of moisturisers in association with barrier creams [5] . Because it has been demonstrated that a damaged skin barrier could be a gateway for COVID-19 [6] , to preserve a high compliance in CDC actions recommended for the prevention of person-to-person viral transmission, dermatologist have the role to educate people to maintain "healthy hands".

title:
  The fear of COVID‐19 infection is the main cause of the new diagnoses of hand eczema: report from the frontline in Milan


id: cord-320929-8h44wf36
author: Sarkar, Rashmi
date: 2020-08-21
txt: ./txt/cord-320929-8h44wf36.txt
cache: ./cache/cord-320929-8h44wf36.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.14220
doi: 10.1111/dth.14220
abstract: nan
summary:
  A live presentation, recorded video, or lecture broadcast online in real-time using the software defines ''webinar''. [3, 4] Online webinars make it interesting for the speakers as well as for the participants in the following ways: Hence webinar is like a ''double-edged sword'' which can be beneficial for some while others (non-qualified healthcare workers and those practicing traditional medicine) can misuse it by implementing the information incorrectly on patients (they are mostly not aware about pharmacokinetics, pharmacodynamics, interactions and contraindications of allopathic medications), especially those without appropriate qualifications and knowledge. Webinars are definitely a game-changer, only if practiced and conducted ethically without doing much damage to the healthcare system. Transition to virtual learning during COVID-19 crisis in Iran: opportunity or challenge Medical Students'' Perceptions and an Anatomy Teacher''s Personal Experience Using an e-Learning Platform for Tutorials During the Covid-19 Crisis Will Virtual Teaching Continue After the COVID-19 Pandemic?

title:
  Webinars as a mode of e‐discussion by Indian dermatologists during the COVID‐19 era: A boon or a bane?


id: cord-322332-0pi3wcv5
author: Conforti, Claudio
date: 2020-05-15
txt: ./txt/cord-322332-0pi3wcv5.txt
cache: ./cache/cord-322332-0pi3wcv5.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13437
doi: 10.1111/dth.13437
abstract: nan
summary:
  An open-label nonrandomized clinical trial suggested that chloroquine and its less toxic metabolite, hydroxychloroquine, may be effective against COVID-19. In fact, in addition to its well-defined antibiotic effects (bacteriostatic action by inhibition of bacterial protein synthesis), in vitro studies have shown doxycycline to exert anti-inflammatory effects at low (20-40 mg/day) and high (100 or 200 mg/day) doses with inhibitory action on metalloproteases and modulating effects of pro-inflammatory cytokines IL-6, IL-8, and tumor necrosis factor-alpha. 7 The anti-inflammatory properties of doxycycline and other components of tetracycline has been demonstrated for several inflammatory airway diseases, including, acute respiratory distress syndrome. 8 Thereby, low doxycycline doses have been shown to be more effective than high doses to prevent induction of pro-inflammatory cytokines (such as IL-6) in inflammatory diseases. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

title:
  Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL‐6 in COVID‐19 outbreak


id: cord-322718-zpf2ri9k
title: Dermatology and specialty rotations: COVID‐19 may reemphasize the importance of internal medicine
author: Goldust, Mohamad
date: 2020-07-11
txt: ./txt/cord-322718-zpf2ri9k.txt
cache: ./cache/cord-322718-zpf2ri9k.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13996
doi: 10.1111/dth.13996
abstract: nan
summary:
  title: Dermatology and specialty rotations: COVID‐19 may reemphasize the importance of internal medicine In most countries including Switzerland, dermatology residency entails five years of training including ward rounds, inpatient care, outpatient consultation, mandatory dissertations, research projects, case presentations, scientific writing and specialists exams -but all pertinent to the subject. Even in the armed forces teaching institutes, serving as a general practitioner is mandatory before dermatology residency to become trained in, internal medicine and infectious diseases. In brief, internal medicine rotations should be made mandatory for dermatologists as this foundation may of use not only for our professional routine but also for exceptional healthcare crisis such as COVID-19. This assumption may reinforced with the SkinSerious Campaign launched by the American Academy of Dermatology which reemphasizes the integral role of dermatologists in health care. Safety Measures in Dermatology Help Minimize Spread of COVID-19 Dermatology Residents and the Care of COVID-19 Patients


id: cord-322963-r0fhnpdn
title: Impact of COVID‐19 outbreak on dermatology services: Dermatology in isolation
author: Katerina, Damevska
date: 2020-05-22
txt: ./txt/cord-322963-r0fhnpdn.txt
cache: ./cache/cord-322963-r0fhnpdn.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13552
doi: 10.1111/dth.13552
abstract: nan
summary:
  1 We present a unique experience from Republic of Macedonia where an abrupt interruption of the dermatology service on a national level, and the COVID-19 outbreak, occurred simultaneously, with a significant impact on the quality of care. The fourth diagnosed case of COVID-19 in the Republic of Macedonia was a dermatologist employed at the University Clinic for Dermatology in Skopje, the only tertiary care hospital in the country. Only 9 dermatologists in secondary care could resume practice in the period from In an effort to discover which of the dermatological conditions demanded immediate attention, we conducted a survey where we asked colleagues about the number and reasons for teledermatological consults. 5, 6 Our survey contributes by presenting the dermatoses, which demanded dermatological consult and which were a diagnostic and therapeutic challenge to the GPs and other specialties. Inpatient care for dermatological patients during SARS-CoV-2-a case report from Portugal


id: cord-323082-p0km31by
title: Callous attitude toward doctors during COVID‐19
author: Jakhar, Deepak
date: 2020-07-07
txt: ./txt/cord-323082-p0km31by.txt
cache: ./cache/cord-323082-p0km31by.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13885
doi: 10.1111/dth.13885
abstract: nan
summary:
  key: cord-323082-p0km31by authors: Jakhar, Deepak; Kaur, Ishmeet title: Callous attitude toward doctors during COVID‐19 date: 2020-07-07 journal: Dermatol Ther DOI: 10.1111/dth.13885 sha: doc_id: 323082 cord_uid: p0km31by The government condemns and issues several notices to stop such acts, but in the absence of a strict law these attacks do not seem to be stopping. More importantly, it is for the general population to understand that doctors do their best, even risk their lives, to deliver the health care services. The authors declare no potential conflict of interest. Death from COVID-19 of 23 health care workers in China More Than 60 Doctors in Italy Have Died in COVID-19 Pandemic Coronaphobia: COVID-19 Warriors Live in Torment Doctor Assaulted Over Death of COVID-19 Patient Coronavirus: India Doctors ''Spat at and Attacked Indian Doctors have an Unexpected Problem While Battling Coronavirus Chennai: Family of Doctor Who Died Due to COVID-19 Not Allowed to Bury Him


id: cord-323965-6mzzibj8
title: COVID‐19 Pandemic: Consensus Guidelines for Preferred Practices in an Aesthetic Clinic
author: Kapoor, Krishan Mohan
date: 2020-05-16
txt: ./txt/cord-323965-6mzzibj8.txt
cache: ./cache/cord-323965-6mzzibj8.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32415753/
doi: 10.1111/dth.13597
summary:
  A set of consensus guidelines for ''preferred practices'' in aesthetic clinics is proposed in this paper for maintaining a high level of safety for the patients coming to the clinic for treatment as well as for the doctors/ therapists performing the procedures. • Small procedure rooms 12 with limited or no natural ventilation • Central air conditioning having a single cooling unit and multiple room vents in most aesthetic clinics, without HEPA (High Efficiency Particulate Air) filtration as present in most operating rooms 13 • Inadequate distance between the patient and treating doctor or therapist 14 • Some of the procedures could take a long time with a patient, e.g., Full Face Ultherapy treatment, Whole body laser hair reduction • Repeated handling of equipment like touch screen, desktop, patient chairs by doctor/therapist and initial screening and handling of patient forms, cash, credit card by the front office staff

abstract:
  BACKGROUND: Strict infection control measures in response to the current COVID‐19 pandemic are expected to remain for an extended period. In aesthetic clinics, most procedures are provided on one to one basis by the physician or therapist. In such a scenario, guidelines detailing the infection control measures for aesthetic clinics are of particular importance. METHODS: An online meeting of an international group of experts in the field of aesthetic medicine, with experience in administration of an aesthetic clinic, was convened. The meeting aimed to provide a set of consensus guidelines to protect clinic staff and patients from SARS‐CoV‐2 infection. RESULTS: Consensus guidelines for ‘preferred practices' were provided for scheduling of patients, patient evaluation and triaging, and for safety precautions about the different procedures. Procedures were categorized into low‐risk, moderate risk, and high‐risk based on the likelihood of transmission of SARS‐CoV‐2 virus from the patient to the treating physician or therapist. CONCLUSIONS: While not intended to be complete or exhaustive, these guidelines provide sound infection control measures for aesthetic practices. Since guidelines regarding safety measures and use of PPEs may vary from country to country, the local guidelines should also be followed to prevent COVID‐19 infection in aesthetic clinics. This article is protected by copyright. All rights reserved.


id: cord-324794-h08uzro4
title: The explosion in scabies cases during COVID‐19 pandemic
author: Kutlu, Ömer
date: 2020-05-23
txt: ./txt/cord-324794-h08uzro4.txt
cache: ./cache/cord-324794-h08uzro4.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13662
doi: 10.1111/dth.13662
abstract: nan
summary:
  2, 3 Recently, we reported that not number but percentages of patients with scabies, psoriasis, urticaria, and scabiesrelated visits to dermatology outpatient clinic increased immediately ten days after COVID-19 pandemic. In the literature, the increasing number of patients with scabies during COVID-19 pandemic has not yet been reported in European countries. Given Turkey''s cultural structure, the lifestyle such as living in the same household with a large number of people, which has become more common due to pandemic-related temporary migration is more frequent than European countries. On the other hand, although the number of patients who requests for outpatient clinics that are not directly related to the pandemic cases decreased in Turkey, most of the hospitals continued to provide healthcare services in all branches of medicine including dermatology. 4 All these factors may be a possible explanation of why Turkey has more scabies cases than European countries. The effect of the "stay-athome" policy on requests for dermatology outpatient clinic visits after the COVID-19 outbreak


id: cord-328090-bprnq9wx
title: Novel coronavirus 2019 (COVID‐19) and epidermolysis bullosa: report of three cases
author: Abdollahimajd, Fahimeh
date: 2020-08-14
txt: ./txt/cord-328090-bprnq9wx.txt
cache: ./cache/cord-328090-bprnq9wx.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.14194
doi: 10.1111/dth.14194
abstract: nan
summary:
  Epidermolysis bullosa (EB) is a skin fragility disorder caused by mutations in genes expressed in the cutaneous basement membrane zone 2, 3 . While an International consensus panel recently provided recommendations for prevention and multidisciplinary care of EB patients during the COVID-19 pandemic 4 , the phenotypic outcome in these patients in comparison to the general population has not been reported; however EB patients, particularly those with syndromic forms, may be at higher risk for infection with severe complications 4, 5 . Thus, the severity of the COVID-19 in these EB patients was in the spectrum experienced by the general population. Phenotypic spectrum of epidermolysis bullosa: The paradigm of syndromic versus non-syndromic skin fragility disorders Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic -Consensus: Recommendations by an international panel of experts Epidermolysis bullosa and the COVID-19 pandemic: challenges and recommendations


id: cord-328718-j9p7ahl8
title: Skin cancer and COVID‐19
author: Goldust, Mohamad
date: 2020-07-23
txt: ./txt/cord-328718-j9p7ahl8.txt
cache: ./cache/cord-328718-j9p7ahl8.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.14050
doi: 10.1111/dth.14050
abstract: nan
summary:
  Some of the worst affected patients include those with chronic illnesses like skin cancers (basal cell carcinoma, squamous cell carcinoma and melanoma). Due to minimal availability of public transport and doctors in regular clinics, several skin cancer patients are going undiagnosed, leading to delayed diagnosis resulting in worsening of its grade and prognosis. Many patients with skin cancer are already immunosuppressed, thus increasing their susceptibility to various infections including COVID-19. 5 Thus, COVID-19 induced stress may predispose patients to squamous cell carcinoma. Newer anti-cancer molecules like immune checkpoint inhibitors (pembrolizumab, ipilimumab, nivolumab) are being used in melanoma 6 but there are reports of pembrolizumab induced neutropenia. 7 This weakens the immune system of patient leading to increased risk of COVID-19. 8 The treatment regimens are also being modified to decrease the need of hospital visits by these patients to reduce the spread of COVID-19 viz. Chronic stress and susceptibility to skin cancer.


id: cord-331687-o5031cxp
title: RAAS blockers in hypertension posing a higher risk towards the COVID‐19
author: Singh, Yogendra
date: 2020-05-02
txt: ./txt/cord-331687-o5031cxp.txt
cache: ./cache/cord-331687-o5031cxp.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32359088/
doi: 10.1111/dth.13501
abstract: nan
summary:
  Most of the hypertensive patients are assisted by angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) or both. A recently published study suggested that COVID-19 also uses ACE2 as a cellular entry receptor, as this was detected in the isolates of the bronchoalveolar lavage fluid of one of the critically ill patients 4 . There is enough evidence to believe that the Zoonotic COVID-19 is completely dependent on human ACE2 as a receptor for entry, thus having high replication potential in human cells. Thus, patients who adhere to RAAS blockers (assisted with ACEi or ARBs) are believed to have a higher risk towards the deadly viral attack of COVID-19, and progressively they must be switched on to other class of anti-hypertensive drugs. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody


id: cord-333684-j1sg46w9
author: Filippi, Federica
date: 2020-06-10
txt: ./txt/cord-333684-j1sg46w9.txt
cache: ./cache/cord-333684-j1sg46w9.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13805
doi: 10.1111/dth.13805
abstract: nan
summary:
  About 750 psoriatic patients assuming biological therapy currently refer to our psoriasis outpatient service, in Sant''Orsola-Malpighi University Hospital, Bologna (Italy), with an average of 80 patients visited weekly. In the screening and monitoring of psoriatic patients, we follow the latest Italian guidelines 3 : blood tests (full blood count, creatinine and electrolytes, liver function tests, serum lipids, fasting glucose) as well as psoriasis disease severity assessment and general physical examination should be performed at baseline and periodically afterwards, on average every 3-4 months, based on clinical judgement, in particular extension of the disease (body surface area, nail involvement, critical areas localization), diagnosis of arthropatic psoriasis, comorbidities and other associated symptoms. Non-urgent blood tests were also suspended, including monitoring in psoriatic patients undergoing biological therapy 7 . If this is not so, it could be the starting point for a further lengthening of the monitoring time of psoriatic patients considered responders to biological therapy.

title:
  COVID‐19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy


id: cord-334933-br1cr8kj
title: Solidarity and transparency against the COVID‐19 pandemic
author: Arora, Gulhima
date: 2020-04-13
txt: ./txt/cord-334933-br1cr8kj.txt
cache: ./cache/cord-334933-br1cr8kj.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32236998/
doi: 10.1111/dth.13359
abstract: nan
summary:
  authors: Arora, Gulhima; Kroumpouzos, George; Kassir, Martin; Jafferany, Mohammad; Lotti, Torello; Sadoughifar, Roxanna; Sitkowska, Zuzanna; Grabbe, Stephan; Goldust, Mohamad 4 Amidst this somber situation, the blame of "politics of epidemics" in which politics mostly attributes to the broad effect of local, national, and international establishments, on the health consequences of communities in disease outbreaks, in Asian countries like India and Iran is challenging. It also works with member states to promote knowledge and empower communities. By working together, countries promote efficiency. Cooperation is a key weapon in the battle against COVID-19. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19) COVID-19: what is next for public health? Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts


id: cord-335104-8b2tpbsh
author: Carugno, Andrea
date: 2020-07-27
txt: ./txt/cord-335104-8b2tpbsh.txt
cache: ./cache/cord-335104-8b2tpbsh.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.14011
doi: 10.1111/dth.14011
abstract: nan
summary:
  authors: Carugno, Andrea; Gambini, Daniele Mario; Raponi, Francesca; Vezzoli, Pamela; Robustelli Test, Elisa; Arosio, Marco Enrico Giovanni; Callegaro, Annapaola; Sena, Paolo title: Coronavirus disease 2019 (COVID‐19) rash in a psoriatic patient treated with Secukinumab: Is there a role for Interleukin 17? Various cutaneous manifestations have been observed in COVID-19 patients 1 and there has been worldwide concern among patients undergoing biologic therapies. [2] [3] [4] We report our experience with a COVID-19 psoriatic patient treated with anti-interleukin-(IL)-17 who developed a late onset rash. About 5 weeks later, he referred to us due to the rapid onset of a mild pruritic erythematooedematous morbilliform rash, rapidly spreading from arms to trunk and lower limbs; he also showed an initial flare-up of his psoriasis The patient developed a mild form of COVID-19, even though his age and comorbidities are most typically associated with poorer prognosis. Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: infection risk and patient counseling in uncertain times

title:
  Coronavirus disease 2019 (COVID‐19) rash in a psoriatic patient treated with Secukinumab: Is there a role for Interleukin 17?


id: cord-336384-sollv92j
title: What does androgenetic alopecia have to do with COVID‐19? An insight into a potential new therapy
author: Goren, Andy
date: 2020-04-08
txt: ./txt/cord-336384-sollv92j.txt
cache: ./cache/cord-336384-sollv92j.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13365
doi: 10.1111/dth.13365
abstract: nan
summary:
  4 In animal studies, it was demonstrated that a sexual dimorphism in fetal pulmonary surfactant production is influenced by the androgen receptor (AR). 5 For example, in rabbits, dihydrotestosterone was shown to inhibit fetal pulmonary surfactant production in both males and females while an anti-androgen, flutamide, was demonstrated to remove the sexual dimorphism in surfactant production. 9, 10 Additional evidence to the possible implication of androgens in COVID-19 infection severity is found in the molecular mechanism required for SARS-CoV-2 infectivity. 11 Previously, it was demonstrated that SARS-CoV-2 cell entry depends on priming of a viral spike surface protein by transmembrane protease serine 2 (TMPRSS2) present in the host. Dihydrotestosterone (DHT) a potent androgen receptor activator and is intracellularly produced in particular cells of tissues such as prostate, hair, and liver that express 5-alpha-reductases, the targeted enzyme for drugs such as dutasteride and finasteride (5-alphareductase inhibitors)


id: cord-336695-jx0waah0
title: COVID‐19: A relationship to climate and environmental conditions?
author: Kroumpouzos, George
date: 2020-04-24
txt: ./txt/cord-336695-jx0waah0.txt
cache: ./cache/cord-336695-jx0waah0.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32276290/
doi: 10.1111/dth.13399
abstract: nan
summary:
  Environmental factors such as temperature and humidity play an important role in progression and spread of severe acute respiratory syndrome (SARS)-CoV infection with the virus retaining its viability for over 5 days at temperatures of 22 C to 25 C and relative humidity (RH) of 40% to 50%. 4, 5 COVID-19, caused by SARS-CoV-2, started in low temperature areas of China, with major outbreaks following in South Korea, Japan, Iran, and Northern Italy. 5 Nevertheless, the dynamics of viral transmission depend on many other factors like physical property of the virus, outdoor and indoor environments, population densities, hygiene, space, and genetic predispositions, which may be the reason for its spread in relatively warmer areas. The effects of temperature and relative humidity on the viability of the SARS coronavirus Effects of air temperature and relative humidity on coronavirus survival on surfaces Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia


id: cord-337382-b3wd182c
title: At home dose escalation of Propranolol for Infantile Hemangiomas during the COVID‐19 Pandemic
author: Bassi, Andrea
date: 2020-07-07
txt: ./txt/cord-337382-b3wd182c.txt
cache: ./cache/cord-337382-b3wd182c.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32633450/
doi: 10.1111/dth.13977
abstract: nan
summary:
  Infantile hemangiomas (IH) often requires urgent evaluation and risk stratification to determine which infants need treatment and which one could be managed with continued observation (5) . As the need for early treatment could be hindered by parents'' fear to access public hospitals during the pandemic period, since the last days of February we encouraged pediatricians and colleagues to send us pictures (via email or WhatsApp) to perform a first screening of patients with higher risk IH needing beta-blocker treatment (5) . In this emergency situation, to avoid unnecessary access to our Hospital heavily engaged in the treatment of COVID-19 patients, we decided, after informed consent, to slowly increase the dose of the drug at home and to monitor the treatment by telemedicine with parents and with the referring pediatrician. Management of Infantile Hemangiomas during the COVID Pandemic


id: cord-338135-zwo7e7gy
author: Melis, Daniele
date: 2020-05-30
txt: ./txt/cord-338135-zwo7e7gy.txt
cache: ./cache/cord-338135-zwo7e7gy.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13722
doi: 10.1111/dth.13722
summary:
  Apremilast is an innovative small-molecule phosphodiesterase 4 inhibitor that has been approved for the treatment of moderate-to-severe plaque psoriasis in adult patients; it has a remarkable efficac y and safety profile and does not require particular screening or follow-up blood tests. 1 The main criticism seems to be its slower activity, in terms of the time required for improvement, with a low rate of Psoriasis Area and Severity Index (PASI) 75 achievement at week 16 in clinical trials: 33.1% of patients in ESTEEM1 and 28% of patients in ESTEEM2. Few real-world studies have investigated the profile of apremilast; [5] [6] [7] [8] [9] there have been no reports of efficacy after 8 weeks of treatment, which we valued as a PASI 50 achievement in 58% of patients and PASI 75 in 19%. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

title:
  Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID‐19 pandemic

abstract:
  Time to improvement is a crucial characteristic for effective treatments of chronic inflammatory conditions, such as psoriasis. Apremilast is a recently approved drug, belonging to the small molecule phosphodiesterase 4 inhibitors, whose optimal safety and efficacy profile is somewhat affected by slow activity rate in clinical trials. Real world case series are suggesting a more consistent improvement, and with this additional personal investigation on 48 patients, we signal that 58% of patients achieved PASI50, and 19% PASI75 improvement in the first 8 weeks of treatment. Results at 16‐week are remarkable, with overall 55% of patients achieving PASI 75, 21% PASI 90 and 14% PASI 100. Only 8 patients (18, 6%) had slightly improved, although satisfied with the regimen, and determined to continue. Noteworthy, our population was rather problematic in terms of comorbidities (86%), and resistance to other treatments, with only 28% naïve to systemics, including biologics. Moreover, the observation period includes the Italian outbreak of COVID‐19 epidemic, and further information on apremilast safety are provided, no one of the patients having stopped treatment. In such a critical period, the apremilast satisfactory speed of therapeutic response in a real‐world setting has further strengthens patient’s compliance to remain safely at home, which is the best strategy to limit contagion. This article is protected by copyright. All rights reserved.


id: cord-338754-xdid58vn
title: Cutaneous manifestations in COVID‐19: a skin rash in a child
author: Olisova, O. Yu
date: 2020-05-30
txt: ./txt/cord-338754-xdid58vn.txt
cache: ./cache/cord-338754-xdid58vn.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13712
doi: 10.1111/dth.13712
abstract: nan
summary:
  Yu; Anpilogova, E.M.; Shnakhova, L.M. title: Cutaneous manifestations in COVID‐19: a skin rash in a child Dr Recalcati made the first report on cutaneous manifestations in COVID-19 nearly a month ago 4 , and since then, several authors have also noticed COVID-19-associated skin rash in adults [5] [6] [7] [8] [9] . However, the data on COVID-19-associated skin disorders in children are scarce. On the second day of fever the PCR COVID-19 test was positive. On the third day of illness the fever dramatically ceased and the skin rash appeared. Along with fever and fatigue, these eruptions may be considered as the only clinical manifestation of these particular COVID-19 infections in children. Cutaneous manifestations in COVID-19: a first perspective Cutaneous manifestations in COVID-19: Lessons learned from current evidence Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection


id: cord-340029-iv2x1vap
author: Farabi, Banu
date: 2020-06-14
txt: ./txt/cord-340029-iv2x1vap.txt
cache: ./cache/cord-340029-iv2x1vap.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13840
doi: 10.1111/dth.13840
abstract: nan
summary:
  showed that there is no death due to COVID-19 and only one hospitalization, fully recovered amongst the patients with chronic plaque psoriasis receiving a biological treatment and renal transplant recipients who were under immunosuppressive therapies (4) . Since, we do not have much data on biologics in psoriasis patients effecting COVID-19 disease course, current data suggests that there is no increase morbidity/ mortality amongst these patients. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies

title:
  Comment on “Psoriasis, COVID‐19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment”


id: cord-340283-5w444i1g
title: Erythematous‐oedematous type of chilblain‐like lesions and COVID‐19 : an Indian perspective
author: Das, Anupam
date: 2020-06-27
txt: ./txt/cord-340283-5w444i1g.txt
cache: ./cache/cord-340283-5w444i1g.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13912
doi: 10.1111/dth.13912
abstract: nan
summary:
  Therefore, the temporal association, complaints of the peculiar neurological sensation followed by development of erythema and swelling in our patients, supports the probable association of the cutaneous manifestations, with COVID-19. 6 In one of the largest series published from Spain, cutaneous manifestations were pseudochilblains (19%), vesicular eruptions (9%), urticaria (19%), maculopapular rashes (47%) and livedo (6%). 7 In another series published from Italy, authors noticed an outbreak of chilblain-like lesions in Italy contemporary to COVID-19 epidemic, who reported two varieties of lesions, namely erythematous-oedematous type and blistering type. Cutaneous manifestations in COVID-19: a first perspective A dermatologic manifestation of COVID-19: transient livedo reticularis Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients Chilblain-like lesions on feet and hands during the COVID-19 Pandemic


id: cord-340474-hbcu72cm
title: Urticaria in the times of COVID‐19
author: Kaushik, Akanksha
date: 2020-06-12
txt: ./txt/cord-340474-hbcu72cm.txt
cache: ./cache/cord-340474-hbcu72cm.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32531079/
doi: 10.1111/dth.13817
abstract: nan
summary:
  2 As per one review, 88/256 (34.3%) patients across 16 studies demonstrated skin manifestations, mostly as erythematous maculopapular rash, urticaria or vesicular rash. 4 While there was a report of one COVID-19 patient presenting with urticaria and dry cough without any fever, 5 the timing of appearance of urticaria was variable, with lesions appearing before, with, as well as >48 hours after onset of fever. [6] [7] [8] [9] Although skin manifestations did not correlate with disease severity in most case reports, 2,6 the prospective This article is protected by copyright. study from Spain suggested that presence of urticaria and maculopapular lesions were associated with more severe COVID 19 illness and a higher (2%) mortality. With an eye on the reported literature, we make a few suggestions regarding urticaria in This article is protected by copyright. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection


id: cord-343739-t3z6ghyp
title: Management of advanced melanoma in the COVID‐19 era
author: Conforti, Claudio
date: 2020-05-14
txt: ./txt/cord-343739-t3z6ghyp.txt
cache: ./cache/cord-343739-t3z6ghyp.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32323399/
doi: 10.1111/dth.13444
abstract: nan
summary:
  key: cord-343739-t3z6ghyp cord_uid: t3z6ghyp For patients undergoing treatment with immunosuppressive or immunomodulating drugs for chronic dermatological diseases, such as psoriasis, several guidelines suggest to assess on a case-by-case basis the initiation of a new therapy with a biological drug as well as the possible suspension in case of positivity. 2 Apart from psoriasis, which can sometimes also be treated in an alternative way, we must focus our attention on the most fragile patients in dermatology, that is, oncologic patients suffering from advanced melanoma. In fact, we should remember that cancer-related treatments may cause immunosuppression, and the first available data suggest that patients with cancer have a risk of excess mortality due to SARS-CoV-2. Coronavirus disease 2019 (COVID-19): facts and controversies COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? Oncology practice during the COVID-19 pandemic AIOM, Rischio infettivo da Coronavirus Covid-19: indicazioni per l''oncologia Cancer patient management during the covid-19 pandemic


id: cord-344566-r75o7ips
title: Evaluation Of Dermatology Consultations In The Era Of COVID19
author: Temiz, Selami Aykut
date: 2020-05-22
txt: ./txt/cord-344566-r75o7ips.txt
cache: ./cache/cord-344566-r75o7ips.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32441360/
doi: 10.1111/dth.13642
summary:
  The number of cases that were suspected to have COVID‐19 was statistically significantly higher in consultations requested by the emergency department and intensive care unit, while there were no suspected cases in outpatient clinic consultations (P = 0.001). In our study, we wanted to evaluate the features such as how dermatology consultations were affected during the COVID-19 pandemic, which is well established in our daily practice, features of the patients consulted, and skin findings in patients with suspected disease. The number of cases that were suspected to have COVID-19 was statistically significantly higher in consultations requested by the emergency department and intensive care unit, while there were no suspected cases in outpatient clinic consultations (p=0.001). With respect to the dermatology consultations in the pre-pandemic literature, it was found that a skin biopsy was performed on 4-13% of the patients (8, 9, 10, 11, 12, 13) . Analysis of Consultation Cases Referred from Pediatrics Department to Dermatology Outpatient Clinic: Retrospective Study

abstract:
  It has been reported that dermatology practices may be a vector for SARS‐CoV‐2 transmission and elective cases should be postponed during the pandemic period. In this context, studies on the change of patient profile in Dermatology outpatient clinic have been conducted. However, there was no study in the literature about dermatology consultations during the pandemic period. 147 Dermatology consultation cases in the era of COVID‐19 pandemic between March 11, 2020 and May 4, 2020 were retrospectively evaluated. 24 patients (16.3%) had suspicion and signs of COVID during consultation (fever, cough, shortness of breath, etc.). 9 (37.5%) of these patients also had accompanying COVID‐19 skin lesions (2 urticarial lesions, 2 livedo and necrosis, 2 maculopapular eruption, 2 vesicular rashes, 1 pseudo‐chilblain). The number of cases that were suspected to have COVID‐19 was statistically significantly higher in consultations requested by the emergency department and intensive care unit, while there were no suspected cases in outpatient clinic consultations (P = 0.001). 2 (1.4%) of these patients were diagnosed with COVID‐19 confirmed by PCR within 2 weeks. We acknowledge that daily practice changes frequently during this period, but still our study provides a perspective to other dermatology clinics in terms of the requested dermatology consultations during the pandemic. This article is protected by copyright. All rights reserved.


id: cord-346159-0bi2f3gb
title: “Thinking outside the box in COVID‐19 era”‐Application of Modified Aerosol Box in Dermatology
author: Babu, Bibilash
date: 2020-06-04
txt: ./txt/cord-346159-0bi2f3gb.txt
cache: ./cache/cord-346159-0bi2f3gb.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13769
doi: 10.1111/dth.13769
abstract: nan
summary:
  In March 2020, Dr. Lai Hsien-yung, a Taiwanese doctor, devised an aerosol box to minimize risk of infection to health care personnel during high aerosol generating procedures like intubation. 5 Currently, many modifications of the original aerosol box have been proposed for application in other fields like dentistry and otorhinolaryngology. Hence, the authors propose a modified design of this aerosol box to assist in performing dermatological procedures on the face like electrocautery, microneedling with a dermapen/dermaroller, chemical peels and lobuloplasty, amongst others. The authors acknowledge that this aerosol box, just like any other device, is not 100% protective or fail proof. It has been proposed to aid in providing protection to the dermatologist, in case the patient inadvertently sneezes/coughs suddenly during a procedure. 10 Hence, we propose the use of this aerosol box, as a precautionary measure, to minimize spread of infection to the maximum possible extent. Face the COVID-19 emergency: measures applied in an Italian Dermatologic Clinic


id: cord-347725-w03ef08b
author: Schwartz, Robert A.
date: 2020-04-16
txt: ./txt/cord-347725-w03ef08b.txt
cache: ./cache/cord-347725-w03ef08b.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32253799/
doi: 10.1111/dth.13380
summary:
  title: Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine A severe cutaneous drug reaction resembling acute generalized exanthematous pustulosis resulting from ingestion of hydroxychloroquine has been documented. Severe potentially life-threatening cutaneous drug reactions are a huge concern, most specifically acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), generalized bullous fixed drug eruption, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation Successful treatment of hydroxychloroquine-induced recalcitrant acute generalized exanthematous pustulosis with cyclosporine: case report and literature review A case of recalcitrant acute generalized exanthematous pustulosis with Sjogren''s syndrome: successfully treated with low-dose cyclosporine Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: case presentation and literature review Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine

title:
  Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine

abstract:
  A severe cutaneous drug reaction resembling acute generalized exanthematous pustulosis resulting from ingestion of hydroxychloroquine has been documented. It is distinguishable by its longer incubation period, more varied morphology with initially urticarial and later targetoid and arcuate plaques, recalcitrance to therapy and longer duration. Given the anticipated surge in the use of hydroxychloroquine due to its reported benefits in those with coronavirus disease 2019, specific recognition of this entity is pivotal. We delineate it as generalized pustular figurate erythema.


id: cord-348430-8xk4dt7t
author: Bragazzi, Nicola Luigi
date: 2020-05-28
txt: ./txt/cord-348430-8xk4dt7t.txt
cache: ./cache/cord-348430-8xk4dt7t.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32415727/
doi: 10.1111/dth.13508
summary:
  To the best of our knowledge, there is a dearth of data concerning the COVID-19 perceptions of dermatological patients under biologics, a therapy traditionally associated to an increased risk of infections. • in psoriatic patients: Psoriasis Area Severity Index (PASI) 14 ≥10 and or Disease Activity index for PSoriatic Arthritis" (DAPSA) 15 Remarkably, in these departments patients undergoing a biological therapy were affecting only by psoriasis (PsO), or atopic dermatitis (AD) or hidradenitis suppurativa (HS). Despite only 8.1% thought that biologics expose them to a moderate to severe risk to contract SARS-CoV2, 18.4% and 21.4% of the whole patients declared that they have assessed the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. 29 In literature, both psoriasis, atopic dermatitis and hidradenitis suppurativa displayed an higher risk of respiratory comorbidities; in accord with this evidence 30% of the interviewed patients thought that their dermatological disease could increase the SARS-CoV2 infection risk.

title:
  COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED‐ZONE declaration

abstract:
  SARS‐CoV‐2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. We aimed to assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID‐19. We performed a cross‐sectional, questionnaire‐based survey on 98/105 consecutive dermatological patients treated with biologics—51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID‐19 related to (a) epidemiology, (b) pathogenesis, (c) clinical symptoms, (d) preventive measures, and (e) attitudes. Patients data and questionnaires were collected. Despite only 8.1% thought that biologics may increase the risk of COVID‐19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients (P = .001) with higher scholarity level (P = .005) displayed higher knowledge of COVID‐19. Patients with lower DLQI (P = .006), longer disease duration (P = .051) and lower scholarity (P = .007) have thought to discontinue/modify autonomously their biologic therapy. At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation vs discontinuation and modification vs no modification, respectively. Dermatologists should promote COVID‐19 knowledge to prevent biologics disruption.


id: cord-348501-8cvtqj7w
title: Rituximab as the treatment of pemphigus vulgaris in the COVID‐19 pandemic era: A narrative review
author: Beyzaee, Amir Mohammad
date: 2020-10-20
txt: ./txt/cord-348501-8cvtqj7w.txt
cache: ./cache/cord-348501-8cvtqj7w.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/33051960/
doi: 10.1111/dth.14405
summary:
  As the immunosuppressive effect of rituximab, the first‐line therapy of PV, lasts more than 6 months, many concerns have raised due to the ongoing novel coronavirus disease (COVID‐19) pandemic. We performed a computer-assisted search of "PubMed" and "Google Scholar" databases up to 14 July 2020 using the keywords "anti-CD20 therapy," "pemphigus vulgaris," and "COVID-19." We also searched other related keywords such as coronavirus, rituximab, immunocompromised, immunosuppressive drugs, pathogenesis, clinical presentations, treatment, and outcome. 17, 18 Athough some studies may have reported that risk of infections is not different between AIBD patients treated with rituximab or high dose corticosteroids, 16 Coronavirus can target the central nervous system (CNS), which is protected by humoral immunity. 31 Also, Guilpain et al reported three systemic sclerosis (SSc) patients treating with rituximab, which resulted to late clinical worsening to severe pneumonia due to the COVID-19 infection.

abstract:
  Pemphigus vulgaris (PV), an autoimmune blistering disease is treated with immunosuppressive medications. As the immunosuppressive effect of rituximab, the first‐line therapy of PV, lasts more than 6 months, many concerns have raised due to the ongoing novel coronavirus disease (COVID‐19) pandemic. With this background, our objective was to review the currently available literature as well as important websites for the evidence related to rituximab, PV and COVID‐19, adverse effects associated with drugs, and relevant guidelines. “PubMed” and “Google Scholar” database were systematically searched for retrieving all articles related to anti‐CD20 therapy in pemphigus vulgaris and COVID‐19 published up to 14 July 2020. A total of seven clinical studies are performed with anti‐CD20 therapy in COVID‐19, three of which are performed on pemphigus patients, and have shown concerns employing rituximab in patients with COVID‐19. Evidence for treating PV patients with rituximab in COVID‐19 pandemic is limited. Until sufficient evidence or guideline for pemphigus and COVID‐19 treatment is available, we advocate caution commencing rituximab in patients with pemphigus, due to the reported adverse outcomes.


id: cord-348846-mfhxac5c
title: Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID‐19 days
author: Coletto, Lavinia Agra
date: 2020-05-02
txt: ./txt/cord-348846-mfhxac5c.txt
cache: ./cache/cord-348846-mfhxac5c.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13415
doi: 10.1111/dth.13415
abstract: nan
summary:
  key: cord-348846-mfhxac5c cord_uid: mfhxac5c Diabetes and metabolic syndrome are acknowledged as associated with PsA and psoriasis 4 ; these comorbidities in the setting of a poorly controlled disease may worsen due to inflammation itself. In conclusion, before interrupting a chronic therapy, even if patients with PsA have an increased risk of comorbidities and serious infections compared with patients with psoriasis, 7 we suggest evaluating not only the infectious profile of immunosuppressants but also the underlying inflammatory nature of psoriatic disease itself, especially if severe and/or associated with articular involvement. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts


id: cord-351457-fzj3ciif
title: Cutaneous lupus erythematosus patients in a high‐epidemic COVID‐19 area, Bergamo, Italy
author: Vezzoli, Pamela
date: 2020-06-07
txt: ./txt/cord-351457-fzj3ciif.txt
cache: ./cache/cord-351457-fzj3ciif.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32506525/
doi: 10.1111/dth.13776
abstract: nan
summary:
  Dear editor, the current pandemic of coronavirus disease 2019 (COVID-19) has raised the interest in reporting the management''s experience with systemic lupus erythematosus (SLE) patients under long-term treatment with immunosuppressor drugs or hydroxychloroquine (HCQ). 5, 6 However, no data about the management of risk infection in cutaneous lupus erythematosus (CLE) during the current pandemic are present in the literature to date. Our hospital is located in a high-epidemic area of Lombardy: we decided to advice patients affected by SLE with cutaneous manifestations and CLE, to scrupulously comply with hygiene rules and protective devices use, to maintain social distancing, not to spontaneously suspend ongoing therapy and to inform the dermatologist in case of the onset of symptoms, as suggested This article is protected by copyright. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19 Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus


id: cord-353659-wtacr6qj
title: Coronavirus Disease‐2019 with Dermatologic Manifestations and Implications: An Unfolding Conundrum
author: Almutairi, Nawaf
date: 2020-05-09
txt: ./txt/cord-353659-wtacr6qj.txt
cache: ./cache/cord-353659-wtacr6qj.txt
extension: .txt
mime: text/plain
url: https://doi.org/10.1111/dth.13544
doi: 10.1111/dth.13544
summary:
  As a nosocomial infection for hospital and nursing home patients and health care workers, it represents an extraordinary challenge. Lungs are the most severely affected organ by COVID-19 because the virus enters the host cells via the integral membrane protein angiotensin-converting enzyme 2 (ACE2), which is attached to cellular membranes in the lungs, arteries, heart, kidney, and intestines. A study of 663 COVID-19 patients from Wuhan, China stressed that patients more than 60 years old and those with chronic diseases were at enhanced risk of severe COVID-19, and more likely to die (43). Clinical Characteristics of Coronavirus Disease 2019 in China Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

abstract:
  The novel coronavirus SARS‐CoV‐2 has caused Coronavirus Disease‐2019, widely known as COVID‐19, now a pandemic with extraordinary infectivity, mortality, and fomite adhesiveness. As a nosocomial infection for hospital and nursing home patients and health care workers, it represents an extraordinary challenge. The cutaneous markers of this pandemic are being elucidated with preliminary experiences being shared and rapidly communicated. We will review COVID‐19 from both a dermatologic and public health perspective. This article is protected by copyright. All rights reserved.


id: cord-355354-1zwgjfc7
title: Mask‐induced psoriasis lesions as Köebner phenomenon during COVID‐19 pandemic
author: Mutalik, Sharad D.
date: 2020-09-29
txt: ./txt/cord-355354-1zwgjfc7.txt
cache: ./cache/cord-355354-1zwgjfc7.txt
extension: .txt
mime: text/plain
url: https://www.ncbi.nlm.nih.gov/pubmed/32959538/
doi: 10.1111/dth.14323
abstract: nan
summary:
  key: cord-355354-1zwgjfc7 title: Mask‐induced psoriasis lesions as Köebner phenomenon during COVID‐19 pandemic cord_uid: 1zwgjfc7 It has been shown that the disruption of a functional and structural permeability barrier is critical for the appearance of psoriasis as Köebner reaction. 4 Accordingly, the importance of the rupturing of the epidermis in initiating the Köebner response has been well documented. Along F I G U R E 1 Well-defined plaque with silvery white scales F I G U R E 2 Face mask with ear loops European task force on contact dermatitis statement on coronavirus 19 disease (COVID-19) outbreak and the risk of adverse cutaneous reactions A case of goggle-mask-related impetigo at the time of the COVID-19 pandemic Koebner phenomenon in psoriasis. Stratum corneum structure and function correlates with phenotype in psoriasis Face mask-induced itch: a self-questionnaire study of 2,315 responders during the COVID-19 pandemic Wearing the N95 mask with a plastic handle reduces pressure 59 injury


